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ABSTRACT
In an effort to find new genetic mechanisms involved in pathogenesis of Small Cell Lung Cancer (SCLC), a differential display technique was used in our molecular biology lab previously.  This experiment showed Inhibitor of DNA/differentiation (Id) 1 gene differentially expressed in a malignant SCLC cell line, Lu-165, comparing to a normal bronchial epithelial cell line, Beas-2b.  Id proteins are negative regulatory members of basis helix-loop-helix family of transcription factors that have important regulatory functions in cell cycle, differentiation in normal development and cancer.
The main aim of this work was investigating the possible role of Id proteins in tumourigenesis of SCLC.  The first part of this thesis established the expression status of Id proteins in SCLC using Western blot and immunohistochemistry techniques.  Western blot showed over-expression of Id1, Id2 to Id3 in 8-9 out of 10 malignant SCLC cell lines comparing to Beas-2b cells. Immunoblot results for Id4 expression was not conclusive.  Immunohistochemical staining of 26 pairs of SCLC/normal bronchial epithelium tissue sections from the same patient demonstrated significant over-expression of all four Id proteins in cytoplasm of malignant cells. But in the nuclei, Id1 was under-expressed, Id3 and Id4 were over-expressed and Id2 was equally expressed in malignant cells comparing to normal epithelium. Survival analysis of 100 immunohistochemically stained SCLC biopsy samples showed longer patients’ survival correlated with higher levels of Id2 but no significant correlation with other Id proteins.  The overall conclusion of this part of study suggested upregulation of Id proteins in SCLC and its association with malignant transformation.
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Figure 1.1:  Incidence and mortality rate of lung cancer in the UK. A) Incidence of most common cancers reported in 2006.  In this year lung cancer occupied the second place after breast cancer and incidence of the disease in men was 1.3 fold higher than that of women.  B) Mortality rate of 20 most common cancer related deaths in 2007.  Lung cancer was the leading cause of death in this category with male to female ratio of 1.3  (http://info.cancerresearchuk.org/cancerstats/incidence/commoncancers ).

Figure 1.2:  In SCC and ACL (NSCLC) sequential  changes occur, causing histologic alterations leading to malignant transformation (sequential theory of cancer development).  In contrast, SCLC might arise from morphologically normal or slightly abnormal epithelium without passing through transitional preneoplastic stages  (parallel theory of cancer development). CIS, carcinoma in situ; AAH, atypical adenomatous hyperplasia; BAC, bronchioalveolar carcinoma (non-invasive adenocarcinoma) (Wistuba et al. 2002).

Figure 1.3:  Haematoxylin and eosin staining of a typical SCLC tumour.  Small cells with scanty cytoplasm, hyperchromatic nuclei with finely dispersed chromatin are characteristic of this cancer.

Figure 1.4: Incidence of SCLC in England and Wales in 100,000 populations for 
male and female, between 1997 and 2006.  While male incidence appear to follow a stable course, female incidence is increasing, reaching that of male gender.  (Data and permission to publish obtained from England National Office for Statistics and Welsh Cancer Intelligence and Surveillance Unit.)

Figure 1.5:  Graphic comparison between incidence of SCLC, other cancers of lung and most common cancers in 2006 in England and Wales, in 100,000 population. (Data and permission to publish obtained from England National Office for Statistics and Welsh Cancer Intelligence and Surveillance Unit.)

Figure 1.6:  Age distribution of SCLC in year 2006 in 100,000 populations in England and Wales, with gender specification.  The disease happened most commonly in the 7th decade of life for both men and women.  (Data and permission to publish obtained from England National Office for Statistics and Welsh Cancer Intelligence and Surveillance Unit.)

Figure 1.7:  Identification of Id1 as a gene over-expressed in SCLC cell lines.  Microquantity differential display analysis of mRNA expression profiles between the malignant SCLC cell line LU-165 and the normal bronchial epithelium cell line Beas-2b. The subset of cDNA containing Id1 fragment (pointed by the arrow) was amplified by 1 of 192 primer pairs. (Ke et. al. unpublished data)

Figure 1.8:  Principal mechanism of Id protein negative regulation of transcription. Forrest, S. and C. McNamara, Arterioscler Thromb Vasc Biol, 2004. 24(11): p. 2014-20.





Figure 2.1: Representative Westernblot experiment to detect protein expression of  A) Id1, B) Id2, C) Id3 and D) Id4 in 10 SCLC cell lines and one normal bronchial epithelium cell line, Beas-2b.  When comparing to the normal beonchial cell line Beas-2b (first in each series), Id1 was over-expressed in 8, Id2 in 8 and Id3 in 9 out of 10 malignant cell lines respectively.  Lu-165 and H-345 malignant cell lines show faint, unmeasurable bands for Id4.  Each panel consist of Id protein expression (top) and β-actin (bottom).  Id1 was detected at 14 KD, Id2 at 17 KD, Id3 at 20 KD and Id4 at 18 KD molecular weights, according to Santa Cruz recommendation.  β-actin was detected at 42 KD as a single band.  The relative expression of each protein in 11 cell lines is shown in Figure 2.2. (Kamalian et al. 2008)

Figure 2.2: Graphic demonstration of relative expression levels of Id1 (A), Id2 (B) and Id3 (C) protein expression in 10 SCLC cell lines and normal epithelial cell line, Beas-2b.  Each expression value is average of 3 separate experiments. Id4 level wasn’t measurable and comparable.  (Kamalian et al. 2008)

Figure 2.3:  Immunohistochemical staining of Id family proteins Id1 (A), Id2 (B), Id3 (C) and Id4 (D) in malignant small cell lung carcinoma tissues (1) and in the corresponding normal bronchial marginal epithelium form the same patient (2). The negative control (3) in each set of experiments was obtained by blocking the staining with different recombinant Id proteins (Kamalian et al. 2008).

Figure 2.4:  Immunohistochemical examination of the expression of different Id proteins in SCLC biopsy samples. A) Nuclear expression of Id proteins. B) Cytoplasmic expression of Id-proteins. Consistent with staining results from the main study, Id1and Id2 showed strong expression in the cytoplasm expression, while Id3 and Id4 were highly expressed in the nuclei (Kamalian et al. 2008).





Figure 4.1:  Principals of RNA interfering technique.  In the initiation phase double strand RNA is processed by the enzyme dicer, making 21-23 short interfering (siRNA) duplexes.  This siRNA is assembled into RISC, recognises the target sequence on the host mRNA and attach to it.  Through endoribouclease activity of RISC the mRNA strand is cleaved (Sontheimer 2005).

Figur 4.2:  p SilencerTM 4.1- CMV neo map, containing ampicillin and neomycin resistance sequences and siRNA insertion site with BamH1 and HindIII restriction sites.  This picture is taken from Ambion p SilencerTM 4.1- CMV neo kit instruction manual.
Figure 4.3:  Id3 Target 18 sequence (A), siRNA silencing constructs (B), and annealed siRNA template insert into plasmid vector (C).

Figure 4.4: Sequencing proved insertion of siRNA oligonucleotide targeting sequence 18 into pSilencer 4.1-CMV neo.

Figure 4.5: Gel electrophoresis of double restriction digestion of plasmid DNA containing si-RNA oligonucleotide insertion.  Column 1 is the DNA marker.  Columns 3-5 are double digested DNA samples containing 55 bp DNA segments.  Columns 6-8 are undigested plasmid DNA corresponding to the same samples in columns 3-5.

Figure 4.6:  DNA gel electrophoresis of double and single restriction digestion of empty vector plasmid DNA.  Columns 1, 2: markers, column 4: undigested DNA, column 5 double digested DNA, Column 6 and 7: HindIII and BamH1 single restriction enzyme digested DNA respectively.  All digestion reactions have produced single bands at approximate molecular weight of pSilencer 4.1-CMV neo, indicating the circularity of the original DNA and its intact restriction sites.  No small bands indicating a short inserted sequence is visible.

Figure 4.7: DNA gel electrophoresis of gradient temperature PCR products to optimize annealing temperature for Id3 primers.  The PCR reaction showed single DNA product amplification across different annealing temperatures indicating suitability of all temperatures within the range for Id3 gene amplification. 


Figure 4.8:  Standard curve for GLC-19 cell line.  The curve equation and regression value of the curve is demonstrated. 

Figure 4.9: Relative expression of Id3 mRNA in transiently transfected cells using different siRNA targets and different experimental length.  According to the graph the target 18 and 20 gave the best knock down.  
Note: Graphs corresponding to target 16/24h, target 21/24h and 21/48 hours were deleted because they showed very high levels of Id3 expression, causing the rest of graphs too small to be comparable.   

Figure 4.10: Relative mRNA expression of Id3 in GLC19 si-Id3 colonies compared to GLC19 parental cells, empty vector (EV), and normal epithelial Beas-2b cell lines.

Figure 4.11:  A) Relative protein expression of Id3 in si-Id3, parental and Empty Vector cell lines.  B) Representative Western blot picture of Id3 protein expression in si-Id3, GLC-19 and empty vector (EV) cell lines. 

Figure 4.12:  Graphic demonstration of relative Id1 and Id2 protein expression in si-Id3 cell lines.  Each column demonstrates the average relative expression value of at least 3 different experiments.  The bars are indicative of standard deviation between values of different experiments.

Figure 4.13: MTS Proliferation Assay:  Graphs show the difference between growth rate of si-Id3 transfected cell lines, GLC-19 parental cell lines and EV control cell line.  Bar lines indicate the standard deviation between triplet samples in each cell line.  The experiment was started with 5000 cells for each cell line.  Final numbers of cells at day 8 are demonstrated.

Figure 4.14:  Graphic demonstration of number of colonies grew in soft agar after seeding similar numbers of si-Id3 transfected cells and Empty vector cells.  The error bars shows the standard deviation between triplicate samples. 

Figure 4.15:  Soft Agar Plates containing colonies produced from GLC-19 parental cells (A), Empty vector control cells (B) and si-Id3 transfected cells, G-Id3-1 and G-Id3-7 (C and D).  Colonies have been stained with MTT for 4 hours. 

Figure 4.16:   Difference in growth and final weight of tumours induced in nude mice by subcutaneous injection of si-Id3 transfected cell lines and Empty Vector control cell line. A) Average of tumour volume in each group as calculated on different days after inoculation. B) Average tumour weights in each group after dissection.  

Figure 4.17: In vivo assay; tumours produced in nude mice after inoculation of si-Id3 cell lines into the animal’s shoulder area.  Each picture is a representative from one group.  Tumour sizes are noticeably smaller in si-Id3 groups compared to the empty vector group.

Figure 4.18:  Degree of apoptosis in empty vector (I), G-Id3-1 (II) and G-Id3-7 (III) cell lines without apoptosis induction.  No apoptosis peaks are detectable in any of the cell lines.

Figure 4.19:  Titration of apoptosis inducing concentrations of champtothecin in empty vector cell line.  Low concentrations of 20 (I), 10 (II), 20 (III) and 30 (IV) µM of champtothecin did not produce any apoptosis peaks in FL1 log.  Champtothecin at higer concentrations of 40 (V) and 60 (VI) µM produced apoptotic cells, indicated as percentage gated in region C of FL1 log.  The lower of these two, 40 µM, was chosen as the optimal concentration to induce apoptosis in the main apoptosis study shown in figure 4.20.








































Table 1.1: WHO classification of neuroendocrine tumours of lung from 1997 to 1999 (Gosney 2000).





Table 2.1:  Immunohistochemical detection of the expression of Id proteins in SCLC and their normal counterparts






Table 4.1: Plating efficiency of GLC-19 cell line in ClonaCell-TSC medium.


Table 4.2: Number of colonies grew at serial concentrations of G418 in ClonaCell-TSC medium after two weeks.

Table 4.3: Summary of final cell count and statistical analysis of MTS proliferation assay using GLC-19 si-Id3 colonies. ρ values are the results of unpaired Student t-test.  

Table 4.4: Number of colonies formed in soft agar counted for si-Id3 transfected cells, GLC-19 parental cells and EV cell line and the ρ value of their difference to EV cell line. 
































Lung cancer is a neoplasm occurring in bronchial epithelium.  According to Cancer Resarch UK, more than 39000 new cases of lung cancer were reported in the UK in 2006, making it the second most common neoplasm after breast cancer.  Lung cancer was responsible for 34,509 deaths out of 155,484 (22%) cancer related deaths in 2007, making it the leading cause of cancer mortality (http://info.cancerrsearchuk.org/cancerstats/incidence/commoncancers).  This data is represented in Figure 1.1.  According to the data taken from US National Cancer Institute website, similar incidence and mortality rate is reported for USA in year 2009 (http://www.cancer.gov/cancertopics/commoncancers).  The incidence of lung cancer in male is twofold higher than female.  Smoking is an established risk factor associated with this disease responsible for 90% of cases (http://info.cancerresearchuk.org/cancerstats/types/lung/).  
Despite its incidence and mortality rate among other cancers, lung cancer research was reported by National Cancer Research Institute (NCRI) as under-investigated. In 2005 among all cancer research targeting a specific type of cancer less than 4% aimed at lung cancer.  Some of the reasons behind this neglect was considered to be the cancer’s reputation for being difficult to study, probably in relation to difficulty in obtaining lung tissue and patients’ short survival that doesn’t give them opportunity to take part in research (NCRI 2006).  
Lung cancer was reported for the first time in 18th century by G.B Morgagni, an anatomist who described a pulmonary tumour from autopsy of a 60 year old male in his famous book of “De sedibus et causis morborum per anatomen indagatis” (Cooper 2005).  It took another 100 years before the first primary lung tumour was diagnosed and reported (Cooper 2005).  The association between pulmonary cancer and tobacco smoking was suggested for the first time by Adler in 1912 (Alder 1912).  However it wasn’t before 1950 when three independent groups made true statistical correlation between lung cancer and cigarette smoking, making it as an important factor in the induction of this disease  ADDIN EN.CITE (Doll et al. 1950; Levin et al. 1950; Wynder et al. 1950).  
The knowledge about the mechanisms through which tobacco caused carcinogenic changes in bronchial epithelium didn’t improve until cytogenetic technology was developed to such extend that was able to identify chromosomal abnormalities such as frequent deletion of 3p in small cell lung cancer (SCLC) in 1982 (Whang-Peng et al. 1982).  Ever since the progress of molecular genetics investigation in lung cancer sped up so that eight of most crucial genes in carcinogenesis of lung cancer were identified by 1989 (Cooper 2005).  
Lung cancer is divided into two main categories of SCLC and non-small cell lung cancer (NSCLC).  These two groups are distinguished clinically and histopathologically and require two different treatment strategies (Cooper 2005).  
NSCLC consist of 75 – 80% of lung cancer, and is divided into some subgroups including squamous cell canrcinoma (SCC), adenocarcinoma of lung (ACL) and 
large cell lung cancer.  These groups are distinguished by their histopathologic characteristics and present different epidemiologic and prognostic picture.  There are also mixed tumours, consisting of SCLC and NSCLC or SCC and ACL.  Located in larger airways, SCC is mainly characterised by intercellular desmosome bridging links and extensive keratinisation.  ACL mostly arises from smaller peripheral airways and consists of cells that produce mucin (Cooper 2005).  SCLC has neuroendocrine properties and its characteristics are explained in details in section 1.3.  

































Figure 1.2: In SCC and ACL (NSCLC) sequential  changes occur, causing histologic alterations leading to malignant transformation (sequential theory of cancer development).  In contrast, SCLC might arise from morphologically normal or slightly abnormal epithelium without passing through transitional preneoplastic stages (parallel theory of cancer development). CIS, carcinoma in situ; AAH, atypical adenomatous hyperplasia; BAC, bronchioalveolar carcinoma (non-invasive adenocarcinoma) (Wistuba et al. 2002).


1.1.2.	Neuroendocrine tumours of the lung


Neuroendocrine (NE) tumours of the lung arise from Kulchitzky cells that are normally present in the bronchial mucosa and share the common morphologic features of neuroendocrine tumors including organoid nesting, palisading, rosettes, or a trabecular growth pattern. They account for 20-25% of all pulmonary tumours and the majority of them are SCLC (Chong et al. 2006). The latest World Health Organisation (WHO) classification for these tumours in 1999, divides them into the main categories of: Typical carcinoid tumour (TC), atypical carcinoid tumour (AC), large cell NE carcinoma (LCNEC) and SCLC.  There are also some other rarer categories in the classification of pulmonary neuroendocrine tumours (Wagenaar 1999).  This classification continued to evolve several times since the first WHO classification in 1967, mostly due to rapidly increasing knowledge of this group of tumours, especially in last two decades  ADDIN EN.CITE (Gosney 2000; Cho et al. 2006) (Table 1.1).  Other classifications have divided these tumours according to their clinical behaviour into three categories of low grade: TC, medium grade: AC and high grade: LCNEC and SCLC  ADDIN EN.CITE (Travis et al. 1991).  Histopathology and clinical observation show that the most differentiated of these lesions is TC with the most benign behaviour while SCLC occupies the other end of the spectrum, displaying the most aggressive behaviour and the most poorly differentiated histopathology type.  The other two categories lie between these extremes with AC closely resembling TC histologically, being more aggressive  and  LCNEC closer to SCLC with less malignant behaviour (Travis et al. 1998). The histopathology characteristics of these four groups are summarised in Table 2. Recent studies have shown that although clinically similar, but TC and SCLC in the NE spectrum are not related entities in epidemiologic, pathologic and molecular terms and AC and LCNEC do not represent intermediate stages (Koutsami et al. 2002).  According to proteomic analysis, the protein expression profile of normal epithelium is close to that of the TC and AC and LCNEC have similar proteomic profile.  SCLC makes a distinctive category and show differences in their proteomics according to tumour stage; it shows some similarity to TC at the very early stage (Cho et al. 2006).  
Table 1.1: WHO classification of neuroendocrine tumours of lung from 1997 to 1999 (Gosney 2000).
WHO 1967	WHO 1982	WHO with IASLC modification 1988	WHO 1999
			NE cell hyperplasia and tumoulets*
			Typical carcinoid tumour
Carcinoid tumour	Carcinoid tumour	Carcinoid tumour	Carcinoid tumour
			Large cell NE Carcinoma
Polygonal/fusiform type SCC	Intermediate type SCC	Small cell/large cell carcinoma	
Lymphocyte-like SCC	Oat cell type SCC	SCC	SCC
Other type SCC	Combined type SCC	Combined type SCC	
			Non-small cell carcinoma with NE differentiation**
			Other tumours with NE properties§
*includes diffuse idiopathic neuroendocrine cell hyperplasia (DIPNECH).**these are morphologically non-neuroendocrine, but with immunochemical or ultrastructural features of neuroendocrine differentiation.§includes pulmonary blastoma, primitive neuroectodermal tumour (PNET), desmoplastic round cell tumour, carcinoma with rhabdoid phonotype and paraganglioma. NE: neuroendocrine, SCC: small cell carcinoma.







Pulmonary site	More central	More central	More peripheral	Most central (>90%)
Carcinoid architecture	Highly organised	Less organised, less uniform	Is retained but more disorganised, lost carcinoid morphology	Absent, but could be traced in large specimens.
Cytoplasm	Copious, finely granular	Similar to TC	--	Minimal
Nucleus	Regular, central	Similar to TC	No moulding	Moulding
Nucleoli	Not noticeble	Similar to TC	Multiple	Rare or absent
Chromatin	Finely dispersed	Similar to TC	Finely or peripherally dispersed	Finely disperse
Mitosis	<2 in 10 HPF	<10 in 10 HPF	> 10 in 10 HPF	80 in 10 HPF
Stromal fibrosis	Focal	More evident	Increases with malignacy	Stroma is full of nucleic acid
Necrosis	Absent	Discrete	More widespread	Wide spread




1.2.	SMALL CELL LUNG CANCER


1.2.1.	History of Small Cell Lung Cancer	







SCLC is a very aggressive disease with frequent widespread metastases.  It is considered a distinct clinicopathologic entity because of many characteristic clinical manifestations, the unique pathologic features and the sensitivity to chemotherapy.  It accounts for over 20% of all bronchogenic carcinomas (Jackman et al. 2005). Of these tumors, 90-95% are central, arising in a lobar or main bronchus (Rosado-de-Christenson et al. 1994).   Affected patients usually have symptoms related to bulky intrathoracic disease, including dyspnea, persistent cough, haemoptysis and postobstructive pneumonia, or features due to invasion of adjacent structures such as dysphagia, hoarseness, and superior vena cava syndrome  ADDIN EN.CITE (Chute et al. 1985; Lassen et al. 1995).  
Diagnosis is based on histology of biopsy samples, usually taken by fine needle aspiration that is 86-91% sensitive and the diagnostic tool of choice  ADDIN EN.CITE (Lassen et al. 1995; Pass et al. 2000)

1.2.2.2.	Histopathology of SCLC













Figure 1.3:  Haematoxylin and eosin staining of a typical SCLC tumour.  Small cells with scanty cytoplasm, hyperchromatic nuclei with finely dispersed chromatin are characteristic of this cancer.

1.2.2.3.	Staging of SCLC
No pre-neoplastic lesion has been specified to SCLC  ADDIN EN.CITE (Travis et al. 1998; Argiris et al. 2001). Surgically dissected samples are rare since treatment is not surgical removal of the tumour after diagnosis  ADDIN EN.CITE (Pass et al. 2000; Jackman et al. 2005).  Therefore instead of the TNM staging system, the system typically used is the Veterans Administration Lung Study Group system.  This classifies the patients into two groups of limited stage and extensive stage disease.  Limited stage disease includes patients whose tumour is apparently restricted to one hemithorax including regional, mediastinal and superaclavicular lymph nodes.  If the disease has spread beyond these areas or distant metastasis are present, it is considered as extensive stage disease.

1.2.2.4.	Treatment
Surgery of SCLC was largely abandoned in the 1970s because the proportion of patients alive at 5 years was less than 5% (Fox et al. 1973).     For patients with limited stage disease, treatment consists of combination chemotherapy, typically etoposide and cisplatin, and radiotherapy.  In extensive stages of SCLC, treatment remains combination chemotherapy (Jackman et al. 2005).   Radiotherapy is reserved for the prevention or treatment of metastases or as palliative/symptom therapy  ADDIN EN.CITE (Jackman et al. 2005; Chong et al. 2006). 

1.2.2.5.	Patient’s outcome and survival
60-70% of patients have extensive disease at diagnosis  ADDIN EN.CITE (Bensch et al. 1968; Koutsami et al. 2002).  Extensive lymph node metastases are frequent, the most common distant metastasis occuring in bone, liver, adrenal glands and brain (Argiris et al. 2001). If untreated, the median survival of these patients is as short as 1.5 – 3 months.  With combination chemotherapy and chest  radiotherapy the median survival increases to 23 months for limited stage disease with 5 years survival rate of 12 -17%.  Patients with extensive stage disease have a median survival of 6-11 months with only 2% alive after 5 years  ADDIN EN.CITE (Johnson et al. 1995; Chute et al. 1999; Janne et al. 2002; Jackman et al. 2005).   Unfortunately, despite all the efforts in the last few decades and the administration of novel molecular approaches to treatment of this cancer the overall survival rate for the patients has remained unchanged since the introduction of chemotherapy in the 1970s  ADDIN EN.CITE (Govindan et al. 2006; Christensen et al. 2009).  





SCLC usually occurs in the 7th decade of life (Chong et al. 2006).  The general incidence of this cancer among other histologic types of lung cancer and the male to female ratio has changed over last few decades.  In The United States the overall incidence of this cancer has dropped from 17.2% in 1986 to 12.95 in 2002.  This decline has been mostly related to the decrease in the prevalence of cigarette smoking, the main risk factor for this cancer, and to the decrease of some of chemicals used in cigarettes particularly nicotine and tar and also popularity of filtered cigarettes.  Male to female ratio that was 2.5:1 in 1973 decreased to 1:1 in 2002 due to a significant increase in female incidence while there is a decrement in male incidence.  This has also been explained by increasing the percentage of cigarette smokers among women.  The proportion of the patients diagnosed with limited stage disease to those who presented with extensive stage has not changed significantly (Govindan et al. 2006).

1.2.3.2.	Incidence in England and Wales
According to combined data obtained from UK National Office for Statistics and Welsh Cancer Intelligence and Surveillance Unit, crude rate of SCLC in 100.000 population for men fluctuated from 11.2 to 13.2 between 1997 and 2006 in England and Wales with an almost stable trend.  Crude rate of the disease in female increased during this period, reaching 11 cases in 100,000 populations in 2005 comparing to some 8.1 in 1997.  Although a slight decrease to 10.2 is observed in 2006, the general trend is increasing to the male rate.  This is similar to what is reported from USA.  This data is graphically demonstrated in figure 1.4.  
Among 750 new cancer cases in 100,000 population in 2006, 139 belonged to bronchopulmonary area from which 22 were diagnosed as SCLC.  This number maked 3% of all cancer types and 16% of lung cancers (Figure 1.5).  
Looking at age specified incidence of SCLC, this also followed the same pattern as has been observed worldwide.  In England and Wales in 2006, the highest rate of incidence of SCLC occurred in 7th decade of life in both genders.  Incidence of the disease was slightly lower at two sides of this peak period, in the 60s and 80s.  The youngest age SCLC was reported was 35-39 age group (Figure 1.6)


Figure 1.4: Incidence of SCLC in England and Wales in 100,000 populations for 
























Figure 1.6:  Age distribution of SCLC in year 2006 in 100,000 populations in England and Wales, with gender specification.  The disease happened most commonly in the 7th decade of life for both men and women.  (Data and permission to publish obtained from England National Office for Statistics and Welsh Cancer Intelligence and Surveillance Unit.)
1.2.3.3.	Smoking and SCLC
Tobacco smoking has been accepted as the major cause of SCLC with positive history in more than 90% of patients  ADDIN EN.CITE (Brownson et al. 1992; Wistuba et al. 2001).  Among all histologic types of lung cancer, the highest relation between cigarettes smoked and cancer incidence is observed in SCLC. This risk is increased by the number of cigarettes smoked per day and number of years over which a patient was smoking (Brownson et al. 1992).   Female smokers have a relatively higher risk of developing SCLC (Koutsami et al. 2002).  This finding is clinically significant, since SCLC incidence appears to be increasing more rapidly in women than in men.
Conversely, there is strong evidence that cessation of smoking reduces the risk of developing all types of lung cancer, with greatest reduction in SCLC. The risk decreases proportionately as the number of years of abstinence from smoking increases.  In relation to gender, women experience greater reduction in the risk of SCLC in relation to abstinence from tobacco smoking.  However the risk in previous smokers approaches, but never reaches that of non-smokers, even after 10 years of smoking cessation.  These findings suggest that cigarette smoking can act as both an initiator and a promoter of lung carcinogenesis (Khuder et al. 2001).  Tobacco smoke contains more than 100 different mutagens and carcinogens that may cause DNA damage, the principal factor in carcinogenesis as well as in all cancers (Shields 2002).  The promoting activity may be diminished immediately but the initiating activity continues to effect for years after the cessation of smoking and maintains the risk higher than non-smokers for ever (Khuder et al. 2001).  Many of the genetic changes that have been detected in histologically normal bronchial epithelium from current and former smokers are absent or very rare in those of true, life-time non-smokers (Wistuba et al. 2001).


1.3.	MOLECULAR GENETICS OF SCLC






There are three forms of this oncogene: C-MYC, N-MYC and L-MYC from which the latter was isolated from SCLC (Pass et al. 2000) although other members of the family are also found in this cancer.  Gene amplification is the main activation mechanism for this oncogene and occurs predominantly in SCLC among all lung tumours, with 20 – 100 copies of the gene per cell (Krystal et al. 1988).  The amplification events are exclusive and occur in 20 – 30% of SCLCs (Johnson et al. 1996).     In 80-90% of SCLC tissue samples there is over-expression of MYC RNA compared to normal lung tissue as result of gene amplification or transcription dysregulation  ADDIN EN.CITE (Pass et al. 2000; Wistuba et al. 2001).   These proteins, members of the helix–loop–helix leucine–zipper (bHLHZ) family, have a role in transcription regulation and are involved in cell proliferation, differentiation and apoptosis  ADDIN EN.CITE (Grandori et al. 2000; Pass et al. 2000; Koutsami et al. 2002; Sanchez-Cespedes 2003). They make transactivating complexes with MAX and repressive complexes with MNT  and MAD proteins (Grandori et al. 2000). The over expression of myc has been associated with poorer survival (Prins et al. 1993).  High expressions  of MYC have been detected in the cell lines derived from metastatic tumours patients and the ones who have relapsed after chemotherapy and this probably explains the relationship with poor survival. Some suggest that this also is an indication of MYC amplification being a late event in the progression of the carcinoma (Noguchi et al. 1990). 

1.3.1.2.	BCL2
BCL2 proto-oncogene is a key member of the apoptotic pathway exerting an anti-apoptotic effect, and its expression is negatively regulated by the tumour-suppressor p53.  Its expression is significantly high in SCLC (75-95%)  ADDIN EN.CITE (Kaiser et al. 1996; Forgacs et al. 2001).  BCL2 usually resides on the outer mitochondrial membrane, endoplasmic reticulum, and nuclear envelope (Neumann et al. 1997).  It belongs to a family of protein that are involved in apoptosis regulation within a normal cell, some of which including BCL2 are anti-apoptosis while others like BAX, BAD and BAC are apoptosis inducers.  BAX a downstream target of  p53 forms a heterodimer with BCL2 that inhibits its function, hence apoptosis (Wu et al. 2002).  The balance between BCL2 and BAX is very important in inducing apoptosis (Koutsami et al. 2002).  In SCLC this balance is inverted with high levels of BCL2 and low levels of BAX.  This is mainly due to  defective p53 (Brambilla et al. 1996).

1.3.1.3.	C-kit





1.3.2.	Tumour Suppressor Genes and SCLC

1.3.2.1.	P53
P53 has been nominated as the guardian of genome, as its function is necessary for maintenance of genomic integrity  ADDIN EN.CITE (Lane 1992; Olsen et al. 2006).  It is a transcription factor that activates upon DNA damage and regulates transcription of different genes involved in cell cycle at the G1/S cell transition, G2/M  DNA damage check point and apoptosis. These include its downstream genes like p21, MDM2, GADD45 and Bax (Levine 1997).  P53 loss of function (mutation or deletion) allows inappropriate survival of genetically damaged cells (Harris 1996).  So it is not surprising that the mutation of this gene is the most common genetic changes in human cancer (several references). The incidence rate of mutation of p53 increases in the spectrum of NE tumours of lung from TC to SCLC (Gosney 2000):  Mutational alteration of the protein is detected in more than 90% of SCLC, most of which in the DNA binding domain of the protein resulting in inability of protein to bind DNA and carry out its trans-regulatory effects on its target genes   ADDIN EN.CITE (Yokota et al. 2004; Joerger et al. 2007).  Mutation in TP53 in lung tumours correlate with cigarette smoking, showing the mutation pattern expected with tobacco carcinogens (Harris 1996). 

1.3.2.2.	Retinoblastoma Protein (RB)
Alterations of RB gene are detected in more than 90% of SCLCs (Osada et al. 2002).  This is almost invariably due to loss of one allele in the RB region on its chromosome and a structural alteration in the other allele Therefore the RB protein is very frequently absent or abnormal in SCLC  ADDIN EN.CITE (Harbour et al. 1988; Yokota et al. 1988; Hensel et al. 1990).  Loss of heterozygocity in RB region is also more frequent in SCLC than other lung cancers (Wistuba et al. 2001).  
 P16-cyclin D1-CDK /RB pathway is one of the most important pathways in cell cycle regulation.  RB sequestrates E2F, a transcription factor containing a consensus binding site for sequences in the promoters of a number of cell-growth control genes, resulting in G1 arrest.  During G1 CD1/ CD2-4 complex activates RB via phosphorylation.  Hyperphosphorylated RB dissociates from E2F, hence G/S transition and cell cycle progress (Forgacs et al. 2001).  Another member of this pathway p16 INK4, which is a CDK4 inhibitor and therefore a tumour suppressor gene, is never impaired in SCLC, while frequently inactivated in other types of lung cancer. It seems that only one part of the pathway is inactivated in any type of lung cancer, in other words, p16 INK4 and RB alterations are mutually exclusive  ADDIN EN.CITE (Kelley et al. 1995).   When RB gene was reconstituted in SCLC cell lines, it was sufficient to suppress the growth of the cells even though several other genetic alterations in the cells remain uncorrected (Ookawa et al. 1993).     
No association has been detected so far between alteration in RB and prognosis of the patient of SCLC nor any relation between RB status and smoking history (Shimizu et al. 1994).

1.3.2.3.	Tumour suppressor genes located on chromosome 3p
The loss of genetic material from the short arm of chromosome 3 is the earliest detected  and most documented genetic change in SCLC.  This is identified in more than 90% of the tumours   ADDIN EN.CITE (Wistuba et al. 2000).  The changes including  homozygous deletion or loss of hetrozygosity, indicating 3p arm carries important tumour suppressor genes (Jackman et al. 2005).  
The most important of these genes that have been identified so far are the fragile histidine triad gene (FHIT), The RAS associated domain family1A (RASSF1A), retinoic acid receptor β (RARβ) and (FUS1).

1.3.2.3.1.	FHIT
It encodes for the enzyme diadenosine triphosphate hydrolase, which might  have an important role in apoptosis and cell cycle (Pekarsky et al. 2002).  The loss of the gene would result in the accumulation of diadenosine tetraphosphate which in turn stimulates DNA synthesis and proliferation (Forgacs et al. 2001).  It is normally expressed in normal lung epithelium. Loss of this protein is detected in majority of SCLC and preneoplastic legions. This helps the notion that this protein might be inactivated at an early stage of the disease  ADDIN EN.CITE (Sozzi et al. 1997).  Interestingly almost in all cases, the aberrant transcripts of this gene is accompanied  by very low levels of wild type mRNA.  This finding is unusual among tumour suppressor genes  ADDIN EN.CITE (Wistuba et al. 2001; Sanchez-Cespedes 2003).   Allelic loss at the encoding region for FHIT is associated with poor prognosis  in SCLC patients (Onuki et al. 1999).  When the enzyme is introduced into cancer cells lacking wild FHIT, it reduces tumour cell growth through induction of apoptosis and cell cycle arrest  ADDIN EN.CITE (Sard et al. 1999).  Loss of hetreozigosity in this genes region are associated with smoking suggesting that it might be a tobacco carcinogenic target (Sanchez-Cespedes 2003). 

1.3.2.3.2.	RASSF1A
The Ras effector homologue, RASSF1A gene is usually inactivated through an epigenetic mechanism of DNA hypermethylation in the promoter region.  It is down regulated in more than 90% of SCLC, mainly through methylation of its promoter sequence  ADDIN EN.CITE (Burbee et al. 2001; Wistuba et al. 2001).  It suppresses the malignant phenotype when is re-introduced to the cancer cells  ADDIN EN.CITE (Dammann et al. 2000). 
Of interest is that RAS proto-oncogene and its lung cancer specificsub-group KRAS are never over expressed or mutated in SCLC (Wistuba et al. 2001), in contrast to non-SCLC which harbour Ras oncogenic mutation in one third of the cases.  However as RASSF1 protein contains a Ras-associated domain, it might act in the Ras-signalling transduction pathway.  This observation might be the first stepping stone towards finding new oncogenes or TSGs associated with RAS cascade in lung tumours (Sanchez-Cespedes 2003). 
1.3.2.3.3.	
1.3.2.3.4.	RARβ
The promoter region of RARβ is methylated in 72% of SCLC cell lines and primary tumours .  Retinoids play an important role in lung development and differentiation.  Its effect which is chemopreventive  in the upper aerodigestive tract epithelium is implemented through nuclear receptors encoded by the RARβ gene (Wistuba et al. 2001).  
Receptors of the RAR family are differentially expressed during development and in adult life, and there is strong evidence that RARß plays a central role in growth regulation of epithelial cells and in tumorigenesis (Roman et al. 1992).

1.3.2.3.5.	FUS1 
This is a candidate tumour suppressor gene that is located on 3p21.3. This gene is frequently deleted or in-activated in SCLC (Jackman et al. 2005). Its specific action is not clear, but is the protein’s myristoylation appears to be necessary for tumour suppression  ADDIN EN.CITE (Uno et al. 2004).   Moreover, tranfection of its wild type into tumour cells results in G1 arrest and growth inhibition  ADDIN EN.CITE (Kondo et al. 2001).  

1.3.2.4.	PTEN/MMAC
This TSG encodes for a tyrosine and lipid phosphatase protein leading to inhibition of PI3K/AKT  pathway, which has the ability to interfere with apoptosis pathway, hence tumour suppression (Cantley et al. 1999).   The genes loss of Heterozygosity was reported in 91% of SCLC cell lines and tumours  ADDIN EN.CITE (Virmani et al. 1998) while homozygous deletion was detected only in very low numbers  ADDIN EN.CITE (Forgacs et al. 1998).  Inactivation of the gene will lift its inhibitory effect on the pathway, resulting in more cell proliferation, anchorage independence and reduced apoptosis.  It has been shown to have tumour suppressor activities in vitro and in vivo  ADDIN EN.CITE (Virmani et al. 1998).   


1.3.3.	Tumour facilitating factors in SCLC

Like any other cancers, in order to proliferate, grow and metastasise, SCLC cells would need factors that facilitate uncontrolled proliferation of cells, inhibit replicative senescence and cellular death,  induce angiogenesis to provide food and oxygen for growing cells and finally help tumour cells to invade neighbouring tissue and distant metastasis.  
Most of the oncogenes and tumour-suppressor genes that were mentioned so far have important role in both initiation and progress of cancer cells, as were explained.  However there are other factors that although don’t come under the category of oncogenes or TSGs, have crucial significance in tumour progression.  Many of these factors have overlapping functions, facilitating the malignant process in more than one single way.

1.3.3.1.	Proliferation 
Growth factors or regulatory peptides and  their receptors are expressed by SCLC or adjacent normal cells in the lung, providing a series of autocrine and paracrine growth loop (Wistuba et al. 2001). 

1.3.3.1.1.	GRP (Gastrin releasing peptide)/ BN (bombesin) 
Different studies have shown 20-60% of SCLCs to express GRP/BN peptide ligands and their corresponding receptors.  Activation of this autocrine system will lead to activation of ERK and JNK cascades, which can promote cell proliferation via anchorage-dependent growth (Osada et al. 2002). Monoclonal antibodies targeting this peptide have demonstrated inhibitory effects on growth of SCLC cells in vitro and in vivo  ADDIN EN.CITE (Cuttitta et al. 1985; Richardson et al. 1993).  Moreover, some studies show a relationship between the expression of GRP receptor and proliferating response to this protein.  Also, there has been an association between the receptor expression and prolong cigarette smoking.  Interestingly the fact that women smokers are more susceptible to develop SCLC than men has been related to GRP signalling, because its receptor is located on X chromosome but does not undergo X inactivation.  So women have two but men have one gene for this receptor  ADDIN EN.CITE (Shriver et al. 2000).  

1.3.3.1.2.	Insulin like growth factor 1 (IGF1)





Telomeres are tandem repeats of 6 nucleotides (TTAGGG) located at the ends of all human chromosomes in all somatic cells.  They shorten through each mitotic cycle, allowing mitotic cell senescence to happen which should finally lead to cell death via p53 mediated apoptosis  ADDIN EN.CITE (Kiyono et al. 1998; Collins et al. 2002). Germ cells and cancer cells maintain telomere length using enzyme telomerase which protect them from senescence, so they continue proliferation which is necessary for tumour progression (Forgacs et al. 2001).  High telomerase activity, which is an indicator of such ability for a cell, is detected in almost 100% of SCLC. This finding leads to conclusion that SCLC mainly consist of immortal cells  ADDIN EN.CITE (Hiyama et al. 1995; Sekido et al. 1998).  Its activity is higher in extensive than in limited SCLC (Hirashima et al. 2001). The telomerase enzyme is made of a RNA subunit (hTR) and a catalytic subunit (hTERT) (Jafri et al. 2004).  Myc oncogene are shown to play an indirect role by transactivating hTERT (Wang et al. 1998).  Also reports suggest that an anti-hTERT gene or genes may be located on 3p, the most frequently altered region in SCLC  ADDIN EN.CITE (Cuthbert et al. 1999).

1.3.3.2.2.	Apoptosis
Normal cells, when are deprived of nutrients and growth factors or face DNA damage, will either repair themselves or undergo programmed cell death. However tumour cells in order to survive acquire the ability to escape apoptosis pathways (Wistuba et al. 2001). In SCLC the apoptotic index is lowest among NE pulmonary tumours (Brambilla et al. 1996).  Key members of apoptoic pathway are p53 and BCL-2 both of which are dys-regulated in SCLC as was described before [reference to the heading number]. Although the correlation of over-expression of BCL-2 and with patient’s short life expectancy is controversial (Koutsami et al. 2002), the presence of BCL-2 might be important for responsiveness to chemotherapy, as it inhibits apoptosis  ADDIN EN.CITE (Ohmori et al. 1993).  A proposed mechanism for this effect is  diminution of mitochondrial transmembrane potential and prevention of release of cytochrome c, an important initiating factor in apoptosis pathway induced by p53 ADDIN EN.CITE (Sartorius et al. 2002).    

1.3.3.3.	Angiogenesis
Tumour cells in order to continue growth and metastasis need oxygen and nutrient.  This is provided by formation of new blood vessels inside growing tumour, a process called angiogenesis.  SCLC is not an exemption in this regard.  However when tumour micro vessel density was used to assess tumour angiogenesis, there was no relation between angiogenesis level and grade of NE tumours  ADDIN EN.CITE (Arbiser et al. 2001).  Moreover, microvessel density was not associated with tumour size, metastasis status or prognosis in SCLC (Eerola et al. 2000).  Inversely, the inducer and inhibitor factors of angiogenesis seem to be important.  

1.3.3.3.1.	VEGF
VEGF is one of the most important growth factors with properties and functions regulating vasculogenesis, hematopoiesis, angiogenesis, lymphngiogenesis, and vascular permeability  ADDIN EN.CITE (Ferrara et al. 1997), all of which involved in tumour progression and metastasis.  VEGF family consists of VEGF and VEGF-B to E and their specific receptors VEGFR1,2 and 3. VEGFR 1and 2 regulates angiogenesis while VEGFR3 is mainly restricted to lymphatic endothelium and regulates lymphangiogenesis (Veikkola et al. 2000). 
Tissue VEGF protein expression induced vessel formation in SCLC cell lines.  High serum levels of this VEGF was correlated with short survival, chemo-resistance and poor prognosis  ADDIN EN.CITE (Salven et al. 1998).  VEGF and VEGFR increased in SCLC cell lines in hypoxic conditions, suggesting that these functional receptors are upregulated when SCLC cells are travelling within hypoxic tissues.  VEGF facilitated SCLC cell migration in vitro indicating its role in tumour metastasis. An autocrine growth stimulation system mediated by VEGF/VEGFR is suggested for SCLC cells (Tanno et al. 2004). 

1.3.3.3.2.	FGF
This family of polypeptides have nine members from which FGF-1 and 2 are well described as regulators of angiogenesis.  By binding to their receptors on cell membrane via heparin sulphate,  FGFs  participate in development, hematopiesis , angiogenesis and wound repair (Friesel et al. 1995).  FGF-b was shown to have synergistic effects with VEGF in vivo  ADDIN EN.CITE (Asahara et al. 1995).  Serum levels of FGF has been significantly correlated with responsiveness to chemotherapy and patient’s prognosis in SCLC  ADDIN EN.CITE (Ueno et al. 2001). 

1.3.3.4.	Invasion 
SCLC is separated from other NE by its high potential to spread quickly (Koutsami et al. 2002).  This employs several extracellular and cell memrane factors involved in cell adhesion, disruption of the extra cellular matrix and cell migration.

1.3.3.4.1.	EGF
Epidermal growth factors including EGF, TGF and AR and their receptor, EGFR play a modulatory role in tumour cell adhesion to ECM proteins via integrins.  Some studies 50% of SCLC cell lines expressed high amounts of EGFR (Damstrup et al. 1992).

1.3.3.4.2.	RTK
Over expression of receptor thyrosine kinases such as c-Kit and c-met increases cellular mobility, motility and proliferation.  
Interaction of c-kit and chemokine CXCR4, promotes motility and cell adhesion in SCLC cell lines  ADDIN EN.CITE (Kijima et al. 2002).  
C-Met, a HGF receptor, is overexpressed in SCLC. it is involved in cellular motility and  invasive growth.  C-Met/HGF complex leads to up-regulation of met-kinase, resulting in cellular proliferation, survival, motility, invasion of ECM, tubule formation and finally metastasis.  C-Met interacts with integrins and several other proteins including P13K and cadherin leads to degradation of cell-cell conections and further promoting metastases  ADDIN EN.CITE (Maulik et al. 2002).  When SCLC cells were treated with HGF their migratory features were enhanced  ADDIN EN.CITE (Maulik et al. 2002).  Also controlling the c-Met/HF axis in SCLC led to changes in cell motility and reactive oxygen species (ROS) production (Sattler et al. 2003).  
1.3.3.4.3.	Integrins
Integrins are transmemberane glycoprotein receptors that allow for adhesion to ECM proteins and other cells (Rintoul et al. 2001).  They consist of  and β subunits, from which, integrin 3β1 is the most common integrin molecule in SCLC  ADDIN EN.CITE (Bartolazzi et al. 1995).  This cancer possess low activation integrins with low affinity for ligands which might be responsible for the detachment and motility of tumour cells (Rintoul et al. 2001), as it has been demonstrated in metastatic models (Palecek et al. 1997).    Integrin 3β1 said to be the most important laminin-binding integrin that anchorages alveolar and bronchial epithelial cells to  basement membrane of human lung (Virtanen et al. 1996).  Low levels of this integrin were associated with high levels of C-MYC, which can be a reason for poor prognosis in SCLCs with high C-MYC expression  ADDIN EN.CITE (Barr et al. 1998).  

1.3.3.4.4.	Plasmin
This is the end-product of a serine protease called u-PA that converts plasminogen into plasmin which in turn leads to  degradation of ECM.  Binding of u-PA to its receptor facilitate tumour cell invasion (Andreasen et al. 1997). The expression of u-PA is correlated with malignant behaviour of NE tumours.  In SCLC stromal expression of this enzyme is correlated with lymph-node metastasis (Bolon et al. 1997).  There are two plasminogen activator inhibitors 1 and 2 from which, PAI-1 is highly expressed in SCLC whilst PAI-2 is elevated in TC, indicating they act in opposite directions in regulating u-PA (Robert et al. 1999). 
1.3.3.4.5.	MMP
Matrix metalloproteinases are members of ECM degrading enzymes that are involved in tumour invasion, metastasis and angiogenesis.  Some studies have shown high levels of MMP 3,11 and14 in SCLC  ADDIN EN.CITE (Michael et al. 1999).

1.3.3.4.6.	Cadherins








1.4.	But the mystery remains!

From this review it is evident that a substantial amount of work has gone into finding more clues regarding the mystery of SCLC.  However finding the  underlying genetic mechanicsm/s that make this cancer so aggressive and disseminative is far from achieved.  Although a lot of questions have been answered and a lot of molecular differences between SCLC and other neoplasms of lung or other organs have been discovered, there is still a fundamental question that is not answered: what is different in this cancer that makes it behave in such an aggressive way?  It seems the proportion of what we know about this devastating disease comparing to the unknown is still nothing.  Therefore looking for new genes and new genetic pathways involved in the pathogenesis of this cancer, which is the main aim of this study, seems to be needed more than ever.


1.5.	Search for a new gene: Id1


Aiming for finding new gene/s involved in pathogenesis of SCLC, a technique called micro-quantity differential display (MDD) was used in the Department of Pathology, using a malignant SCLC cell line, LU-165 and a normal epithelial cell line, Beas-2b, to identify gene/s which are differentially expressed between these two cell lines.  
MDD (Jing et al. 2000) is an evolved sequel of  differential display technique which was invented in 1992 by Liang and Pardee (Liang et al. 1992).  Differential display basically utilises a set of oligonucleotide primers, one that anchors to the poly-A tail of a subset of mRNAs, and one that is short with arbitrary sequence, therefore could anneal at different positions relative to the first primer. The mRNA subpopulations defined by these primer pairs are amplified after reverse transcription and resolved on a DNA sequencing gel (Liang et al. 1992).  





















These proteins belong to superclass 1 transcription factors.  They contain a highly conserved HLH region that mediates protein-protein interaction as well as a DNA binding domain.  In order to activate transcription, bHLH proteins bind to each other forming homodimers or heterodimers, which through DNA binding domain will bind to special sequences  (CANNTG) called E-boxes in the promoter region of corresponding gene (Forrest et al. 2004).  bHLH protein are further subclassified into seven classes, class I to VII.  This classification is based on tissue distribution, DNA binding and dimerization capabilities (Murre et al. 1994).  













Figure 1.8: Principal mechanism of Id protein negative regulation of transcription. Forrest, S. and C. McNamara, Arterioscler Thromb Vasc Biol, 2004. 24(11): p. 2014-20.

Id proteins mainly target class I bHLH factors, although class II proteins that are mostly incapable of making homodimers  ADDIN EN.CITE (Murre et al. 1989), are indirectly inhibited by sequestration of class I proteins (Forrest et al. 2004).  Id proteins can also target some of class III HLH factors as well as some transcription factors  not containing HLH domain such as ETS  ADDIN EN.CITE (Yates et al. 1999), PAX  ADDIN EN.CITE (Roberts et al. 2001) and pRB  ADDIN EN.CITE (Iavarone et al. 1994; Lasorella et al. 1996).  

1.6.3.	Pathways Involving Id Proteins

1.6.3.1.	RB/E2E pathway
A key regulator of G0 to S phase transition is the retinoblastoma tumour suppressor protein (pRB) as well as the RB family members p107 and p130  ADDIN EN.CITE (Mulligan et al. 1998; Vooijs et al. 1999).  RB, in order to stop cell cycle progression binds to and stop a transcription factor E2F whose function is the activation of factors critical for S phase transition (Vooijs et al. 1999).    Id2, but not Id1 or Id3, through its HLH domain, is capable of binding to pocket domain of pRB, inhibiting its negative regulation on E2F and cell proliferation  ADDIN EN.CITE (Lasorella et al. 1996). The activity of RB family protein is mainly regulated by cyclin-dependent kinases (CDKs) in conjunction with their regulatory cyclin partners (Sherr 1996).  Activation of these factors will facilitate phosphorylation of pocket domains of RB and subsequently prevent it from binding to E2F transcription factor  ADDIN EN.CITE (Harbour et al. 1999). In turn, CDKs are regulated by other factors that lead to next pathway series involving Id proteins.
1.6.3.2.	CDKI/CDK pathway























Figure 1.9:  RB/E2F pathway of cell cycle regulation.  Id2 inhibits RB directly by binding to its pocket domain, while Id1 and Id3 inhibit RB indirectly by inhibiting the activators of CDKIs such as E2A and ETS.  (Copied and modified from: Zebedee, Z. and E. Hara, Oncogene, 2001. 20(58): p. 8317-25)

1.6.3.3.	TGFβ/BMP/Smad Pathway




1.6.4.1.	Ubiquitin - proteosome proteolysis
Id proteins are generally short-lived, with half-lives ranging from 20 to 60 minutes, depending on the cell type.  They are stabilized by forming dimers with bHLH factors (Yokota et al. 2002).  The rapid degradation which indicates the importance of precise regulation of these proteins in the cell is due to proteolysis through the ubiquitin-proteasome pathway.   This is a mechanism within cells that facilitates protein degredation by means of a large protein complex called 26S proteasome.  This proteasome recognizes target proteins that are tagged by addition of ubiquitin molecules and will degrade them into small peptides.  The function of the 26S proteosome is important in relation to its rapid degradation of certain regulatory proteins in the stringent control of their signaling activity (Bounpheng et al. 1999).  
Id1, 2 and 3 are ubiquitinated  by a ubiquitin-activating enzyme and then degraded by 26S proteasome, Id4 is ubiquitinated the same way but is not sensitive to 26S proteasome inhibitors (Yokota et al. 2002).  It is suggested that although this protein is still modified by ubiquination, other mechanisms should be involved in Id4 degradation (Bounpheng et al. 1999).  The anaphase promoting complex/cyclosome (APC/C),  a classic cell cycle regulator,  was the first ubiquitin ligase discovered priming  Id proteins for proteasomal-mediated degredation. APC/C and its co-activator CDH1 recognizes Id1, 2 and 4 but not Id3 through a highly conserved destruction D box motif, located at C-terminal side of HLH domain.  Mutations in Id2 D box resulted in stabilization of the protein.  In relation to Id3, since it is still a subsrate of the ubiquitin proteasome system, another unknown ubiquitin ligase must be involved priming this protein for degradation  ADDIN EN.CITE (Lasorella et al. 2006). 

1.6.4.2.	Nucleo-cytoplasmic shuttling  
For many proteins, their subcellular localization is crucial for their function.  Large proteins shuttle between nucleus and cytoplasm by means of their intrinsic nuclear localization signals and nuclear export signals.  In contrast small molecules like Id proteins (13 – 18 kDa) can freely pass through the nuclear membrane.  However, other regulatory pathways rather than passive diffusion seem to be involved in deciding the subcellular localization of Id proteins.  Id1 and Id2 are predominantly cytoplasmic when passive diffusion into the nucleus is blocked  ADDIN EN.CITE (Kurooka et al. 2005; Makita et al. 2006).  It was demonstrated that Id1 and Id2 may be regulated by nucleo-cytoplasmic shuttling, via their specific nuclear export signal system, which is structurally different between the two proteins. Therefore Id1 and Id2 are regulated via different molecular elements ADDIN EN.CITE (Kurooka et al. 2005; Makita et al. 2006).  Another study has reported that protein kinase A controls the process of nucleo-cytoplasmic shuttling of Id1 during angiogenesis, blocking its nuclear export (Nishiyama et al. 2007).   Id3 and Id4 have seen to maintain their nucleo-cytoplasmic distribution, even when passive infusion is blocked.  They lack functional nuclear export signal and their subcellular localization is determined by passive diffusion and interaction with E proteins  ADDIN EN.CITE (Kurooka et al. 2005). 

1.6.4.3.	Cytoplasmic sequestration
There is evidence that cytoplasmic proteins with Id-anchoring capability regulate Id proteins by keeping them in the cytoplasm, where they are inactive (Deed et al. 1996).  The cytoplasmic proteins enigma homolog (ENH) and polycystin-2 (PC2), both associated with the actin cytoskeleton, bind Id2 and sequester it into the cytoplasm  ADDIN EN.CITE (Li et al. 2005; Lasorella et al. 2006).  The other Id-anchoring protein is interferon-inducible protein p204.  This protein binds to Id proteins during skeletal and cardiac muscle differentiation and prevents it from interaction with its nuclear targets.  This protein also facilitate ubiquitin mediated degradation of Id3 through an unkown ubiquitin ligase  ADDIN EN.CITE (Ding et al. 2006).  

1.6.4.4.	Id/E protein heterodimerization
E proteins such as E47 possess a classical nuclear localization signal and are found exclusively in the cell nucleus (Littlewood et al. 1994).  Inversely, Id proteins lack such a nuclear localization signal and are distributed in both the nucleus and cytoplasm depending on physiological conditions of the growing cells  ADDIN EN.CITE (Iavarone et al. 1994).  E47 chaperones the Id proteins into the nucleus by constructing heterodimeres.  This increased the half-life of Id to three hours while substantially decreasing the half-life of E proteins.  However, it appears that it is the heterodimerization, rather than the localization that prolongs Id’s life (Deed et al. 1996).  

1.6.5.	Footprint of Id Proteins in Different Cancers

Dysregulation of Id proteins and/or their mRNA level has been reported in many cancers.  Id1, Id2 and Id3 proteins were generally downregulated in hepatocellular carcinoma and were more expressed in more differentiated tumors  ADDIN EN.CITE (Damdinsuren et al. 2005).   All four Id proteins were dysregulated in prostate cancer and there was a higher risk of metastasis with higher expression of Id4 (Yuen et al. 2006).  In ovarian cancer the level of Id-1 protein expression correlated with the malignant potential the tumors i.e. stronger Id-1 expression was associated with poor differentiation and more aggressive behaviour of tumour cells, resulting in poor clinical outcome  ADDIN EN.CITE (Schindl et al. 2003).  Id1 also could serve as a marker for the aggressiveness of breast cancer (Lin et al. 2000).  The level of Id1, Id2 and Id3 mRNA showed increase in pancreatic cancer in comparison to normal pancreas  ADDIN EN.CITE (Maruyama et al. 1999).  In squamous cell carcinoma of head and neck Id1, 2 and 3 were associated with poor differentiation (Langlands et al. 2000).  Over-expression of Id-1 was an independent marker for tumour progression in cervical cancer  ADDIN EN.CITE (Schindl et al. 2001).  The Id-1 gene was over-expressed in papillary thyroid cancer and also might play a role in the regulation of growth in papillary thyroid cancer (Kebebew et al. 2003).  The expression of Id1, Id2 and Id3 has been found to be significantly elevated in primary human colorectal adenocarcinomas when compared with normal mucosa, and correlated with the presence of mutated p53  ADDIN EN.CITE (Wilson et al. 2001).  Upregulation of Id1 has been detected in early melanoma in correlation with low levels of p16 (Polsky et al. 2001). High levels of Id2 transcripts were detected in Ewing sarcoma cell lines and tumor tissues and its level was activated by WS/ets chimeric proteins  ADDIN EN.CITE (Fukuma et al. 2003). High expression of Id1 was associated with more malignant behaviour, less differentiation and poor prognosis in endometrial carcinoma (Takai et al. 2001).  All four Id proteins were upregulated in malignant seminoma  ADDIN EN.CITE (Sablitzky et al. 1998). Strong Id1 expression in gastric carcinoma was associated with poor differentiation and adverse prognosis  ADDIN EN.CITE (Han et al. 2004). Id2 and Id3 were overexpressed in T cell leukaemia  ADDIN EN.CITE (Ishiguro et al. 1995). Id2 overexpression was a strong predictor for poor prognosis in childhood neuroblastoma irrespective of the clinical or biological variables. such as patient’s age and N-MYC amplification  ADDIN EN.CITE (Lasorella et al. 2002). To date, there is no documented investigation about the expression of Id proteins in small cell lung cancer.

1.6.6.	Tumourigenic Properties of Id Proteins
Ids are fetal markers, and their expression is commonly low or absent in differentiated cells  ADDIN EN.CITE (Yokota 2001; Zebedee et al. 2001), so it is said that “re-expression of them in tumour cells and tumour stroma indicates the re-version to an earlier embryonic state in which the proliferative and migratory potential of the cells and the rapid acquisition of blood-vessels support facilitates the transformation process in  human disease”  (Perk et al. 2005).
Two functions of Id proteins, stimulation of proliferation and inhibition of differentiation in some settings are enough to turn cells into immortal status or induce oncogenic transformation  ADDIN EN.CITE (Lasorella et al. 2001). However Ids have been proven to have other capabilities which are in favour of tumourigenesis.  The most important ones would be their involvement in apoptosis and cell senescence, angiogenesis and tissue invasiveness, which are crucial factors in formation and maintenance of malignant tumors. When dysregulated, using all these capabilities, Id proteins can lead the cell into malignant transformation.

1.6.6.1.	Id proteins and proliferation 
Id proteins are essential for progression of the cell cycle in cell culture, it is reported that every proliferating cell type in culture expresses one of Id genes (Perk et al. 2005).  Growth stimulation causes Id upregulation (Norton et al. 1998). Id1 and Id2 are low in quiescent fibroblasts, but induction of mitogenic signaling with serum or growth factor results in Id over-expression, suggesting their involvement in G0–S transition  ADDIN EN.CITE (Hara et al. 1994).  When this response is inhibited by silencing Id1 and 2, cells are prevented from entering S phase (Barone et al. 1994). There is evidence that expression of Id in different cancer cells enhances cell proliferation. Partial elimination of Id2 in neuroblastoma  ADDIN EN.CITE (Lasorella et al. 2002), in pancreatic carcinoma (Kleeff et al. 1998) and Id1 in mammary carcinoma (Lin et al. 2000) decreases proliferation. 
The most important mechanisms identified to date relating Id protein to regulation of cell cycle and proliferation include: In mammalian cells a crucial checkpoint control for proliferation is provided by the three pocket proteins of the RB family (RB, p107 and p130) (Sherr 1996). Through these pocket proteins, RB will bind to E2F transcription factor, inhibiting it from activating genes that are essential for cell cycle progression (Sherr 1996). Id2 can bind to each of these pocket proteins  ADDIN EN.CITE (Lasorella et al. 1996).  In normal circumstances RB has a restraining role on Id2 (Benezra 2001). However when in excess, Id2 can bind to pocket proteins and release E2F from RB, resulting in cell proliferation  ADDIN EN.CITE (Lasorella et al. 2001).  Id4 also seems to antagonize RB family members (Norton 2000) but despite the fact that all members of the Id protein family have similar biological activity (Norton 2000), Id1 and Id3 don’t seem to relate directly to RB  ADDIN EN.CITE (Iavarone et al. 1994).  
Id proteins can indirectly interfere with RB pathway by inhibiting different CDKIs including p21, p16 and p27.  For instance, p21 contains E boxes on its promoter region, which are usually binding sites for bHLH factors such as MyoD  ADDIN EN.CITE (Prabhu et al. 1997).  In skeletal muscle cells elevated levels of p21 are associated with cell differentiation and cell cycle arrest  ADDIN EN.CITE (Halevy et al. 1995).  In the presence of Id1 this effect is blocked leading cell to cell cycle progression, probably due to activity of CDKs taht are not opposed by p21, which in turns inhibit RB by phosphorylation  ADDIN EN.CITE (Prabhu et al. 1997).  In a wounding model, Id3 was found to regulate levels of p27 during cell cycle changes.  Silencing of Id3 reversed p27 downregulation induced by injury, resulting in blocking proliferation process (Chassot et al. 2007). In nasopharyngeal carcinoma Id1 overexpression was associated with p27 suppression  ADDIN EN.CITE (Wang et al. 2002).  Id1 was found to control expression of p16 in senescent fibroblasts via inhibition of ETS proteins  ADDIN EN.CITE (Ohtani et al. 2001).  
There is also in vivo evidence for regulatory effect of Ids on CDKIs.  For example Id2–/– mammary epithelial cells are defective in proliferation during pregnancy and this is associated with elevated levels of P21 and p27 (Mori et al. 2000).  

1.6.6.2.	Id proteins and anaplasia
Tumour cells use various strategies to disrupt pathways leading to terminal differentiation, a process called anaplasia  ADDIN EN.CITE (Lasorella et al. 2001).  Usually this is associated with the ability to  constitutively activate growth signalling (Evan et al. 2001).   
It is widely assumed that Id proteins are low or undetectable in post-mitotic, differentiated cells (Norton 2000).  However there has been reports that there are exceptions.  Id2 and Id4 have been reported to be expressed by a variety of differentiating cell types from the neuroectodermal lineage.  Therefore  it has been speculated that Id proteins might have tissue specific functions in these cells  ADDIN EN.CITE (Lasorella et al. 2001). 
There are evidences for inhibition of differentiation caused by overexpression of Id protein, such as ectopic Id genes that cause inhibition of differentiation of several cell types in culture such as muscle (Jen et al. 1992) myeloid cells (Jen et al. 1992) and murine erythroleukemia cells  ADDIN EN.CITE (Shoji et al. 1994)
In vivo, Overexpression of Id2 directed ectodermal precursors into neural rather than epidermal lineage in the chick (Martinsen et al. 1998).  Overexpression of Id1 in embryonic mouse brains caused impairment in neuronal differentiation  ADDIN EN.CITE (Cai et al. 2000) and in lymphoid progenitors of transgenic mice led to an arrest at the pro-B cell stage of development (Sun 1994).  Also bipotential T/natural killer progenitor cells that constitutively express Id3 follow an NK fate  ADDIN EN.CITE (Heemskerk et al. 1997).  Id1-/- Id3-/- mouse embryos ended up with premature neuronal differentiation  ADDIN EN.CITE (Lyden et al. 1999).  Therefore we can conclude that overexpression of Id proteins in tumour cells will have a pronounced effect on the differentiation state of the cell.  It is said that overexpression of Ids in tumour cells might be able to revert cells to an earlier stem like state thereby facilitating long-term tumour growth or progression (Perk et al. 2005).  Overexpression of Id have been correlated with high grade/poor differentiation grade of many tumours, for example Id1 in prostate (Forootan et al. 2007) and  epithelial ovarian tumour  ADDIN EN.CITE (Schindl et al. 2001), as well as Id1 and Id3 in astrocytic tumour   ADDIN EN.CITE (Vandeputte et al. 2002).  

1.6.6.3.	Id proteins, cell senescence and apoptosis
Most somatic cells are not able to continue dividing indefinitely and have to stop after a certain number of cell division.  This state is called  replicative senescence in which cells arrest in G1 phase, and never enter S phase.  These cells are still alive and have active methabolism (Campisi 1996).  Most tumour cells seems to have escaped senescence mechanism and are able to divide indefinitely  ADDIN EN.CITE (Campisi 1996; Dimri et al. 1996).  When a cell is immortalized or acquire an unusually long mitotic life span, successive mutations needed for malignant transformation have greater chance to occur.  Thus cellular senscense is counted as a barrier against cancer  ADDIN EN.CITE (Zebedee et al. 2001). Escaping senescence is one of the early mechanisms leading to malignant transformation  ADDIN EN.CITE (Wong et al. 2004). Introducing an oncogene or oncogenic stimulation will induce cell cycle arrest which is called premature senescence  ADDIN EN.CITE (Zebedee et al. 2001). Telomere shortening, p53 and RB tumour suppressor pathways are responsible for maintaining and inducing replicative senescence  ADDIN EN.CITE (Wong et al. 2004).  In human these pathways are overlapping, therefore inactivation of both pathways is required to override senescece (Shay et al. 1991).  One of the pathways related to RB induced senescence is through p16INK4A because overexpression of p16 is reported to be associated with senescence  ADDIN EN.CITE (Hara et al. 1994).  Id proteins have been shown to have a say in regulation of cell senescence.  Loss of Id function been related to replicative senescence  ADDIN EN.CITE (Hara et al. 1994).  Forced expression of Id1 in human primary keratinocytes caused extension of replicative lifespan of the cells and this was associated with increased phosphorylation of RB and suppressed levels of  p16  ADDIN EN.CITE (Alani et al. 1999; Nickoloff et al. 2000) but was not associated with increased telomerase activity  ADDIN EN.CITE (Nickoloff et al. 2000; Tang et al. 2003).  The mechanism through which Id1 inhibits p16 is by inactivation of ETS, some publications suggest this is related to premature senescence, while regarding replicative senescence activation of tumour promoting MAPK signalling pathway is important  ADDIN EN.CITE (Ohtani et al. 2001). Id1 co-operate with a pRB binding mutant of SV40 large T antigen to reactivate DNA synthesis in senescent human fibroblasts  ADDIN EN.CITE (Hara et al. 1996).  That Id1 alone is not able to achive immortalization indicates that additional factors are required to co-operate with Id1 to overcome replicative senescence  ADDIN EN.CITE (Wong et al. 2004).  Co-transfection of Id1 and antiapoptotic factor BCL-2 leads to immortalization of primary rodent fibroblasts (Norton et al. 1998).   The effect of Id proteins on induction of apoptosis is controversial.  Some studies mostly using non-epithelial cells indicated that Id1 over-expression was associated with apoptosis.  However cancer studies on prostate cancer showed that Id1 protected cells against apoptosis and when was blocked the rate of apoptosis increase  ADDIN EN.CITE (Wong et al. 2004).  Id3 also has shown similar reverse effects in relation to apoptosis. Ectopic Id3 in immortalized human keratinocytes induced apoptosis which was associated with activation of caspase 3 and 9  ADDIN EN.CITE (Simbulan-Rosenthal et al. 2006).  Inversely when Id3 was depleted in neural crest cells of xenopus embryo model, it was associated with increased apoptosis  ADDIN EN.CITE (Kee et al. 2005).  Therefore it is suggested that the antiapoptotic activity of Id is cell type dependent  ADDIN EN.CITE (Wong et al. 2004). 

1.6.6.4.	Id proteins and tumour angiogenesis
The ability to promote growth of new vessels is essential for a mammalian cell to transform into malignant phenotype (Hanahan et al. 2000).  This is to provide supplement for the expanding tumour mass.  Id proteins seem to be required for this process.  
In a series of in vivo experiments reported by Lyden et al, Id3 -/- Id1-/- double knockout mice died in early gestation age due to severe vascular abnormalities.  Id3+/- Id1-/- mice were viable but when were inoculated by different tumour cells, the tumour formation was profoundly impaired due to a significant decrease in vascularization and angiogenesis.  The blood vessels lack the ability to branch and sprout and form normal calibre lumens during tumor progression and as a result there was a considerable necrosis among tumour cells. This was the first in-vivo evidence that Id3 is critical to the vasculature  ADDIN EN.CITE (Lyden et al. 1999).  
Angiogenesis is a complex process involving various cellular events such as growth, differentiation, migration, and morphogenesis (Risau 1997).  Vascular endothelial growth factor (VEGF) and its receptors have crucial involvement in all these stages  ADDIN EN.CITE (Benezra et al. 2001). Endothelial cells (ECs), on the other hand, play a principal role in angiogenesis, giving rise to vascular extensions from the existing vasculature by sprouting and intussusceptions (Risau 1997).  ECs receive extracellular signals such as VEGF and angiopoietin with their receptors, thereby responding via intracellular signalling pathways and leading to changes in cellular behaviour appropriate for vascular network formation (Risau 1997). In the nucleus, various transcriptional factors function to control gene expression, which contributes to the angiogenic property of ECs  ADDIN EN.CITE (Risau 1997; Oettgen 2001).  Ectopic expression of Id1 in ECs enchanced angiogenisity in both in vitro and in vivo angiogenesis models  ADDIN EN.CITE (Nishiyama et al. 2005).  
The other important element in neoangiogenesis is mobilization of bone marrow precursor cells.  This is also stimulated by VEGF  ADDIN EN.CITE (Benezra et al. 2001).  There are strong evidences that VEGF stimulation upregulates Id1 and Id3 proteins which promotes angiogenesis, in part by inducing mobilization and recruitment of bone marrow derived cells to tumour vasculature  ADDIN EN.CITE (Benezra et al. 2001).  The evidence for this notion comes from the observation that VEGF induced mobilization of endothelial precursor cells is completely impaired in Id mutant mice.  In wild type mice, bone marrow transplantation with Id mutant bone marrow resulted in significant delay in tumour growth  ADDIN EN.CITE (Benezra et al. 2001).  On the other hand, some studies have reported that VEGF might be downstream target of Id1 protein.  Ectopic expression of Id1 in a prostate cancer cell line with low levels of Id and VEGF, resulted in activation of VEGF transcription, and this increased in higher VEGF and also growth and tube formation of endothelial cells.  Inversely when they silenced Id1 expression with si-RNA, both VEGF transcription and protein level decreased  ADDIN EN.CITE (Ling et al. 2005).  Therefore we can say that there is convincing evidence for a cooperative action of Id1 and Id3 in neoangiogenesis.  
The mechanism underlying the function and control of  Ids in angiogenesis is still unclear (Nishiyama et al. 2007).  Some molecules such as  α6 and β4 integrins, MMP2, fibroblast growth factor receptor 1  ADDIN EN.CITE (Ruzinova et al. 2003), chemokine receptor 4 (Sikder et al. 2003) and angiopoietin-1  ADDIN EN.CITE (Nishiyama et al. 2005) have been suggested to be downstream molecules of Id protein.  There was lack of MMP2 and avb3 integrin expression detected in vessels formed in Id1 and Id3 double knock down mice which may provide an explanation  for the angiogenic defect  ADDIN EN.CITE (Lyden et al. 1999), since MMPs or angiogenic factors may be required for functional integration of bone marrow derived precursor cells into new vasculature  ADDIN EN.CITE (Benezra et al. 2001). Thus Id might be involved directly or indirectly, in controlling these molecules which are required for tumour growth and metastasis  ADDIN EN.CITE (Brooks et al. 1994).  An additional pathway proposed for Id mediated angiogenesis is through repression of thrombospondin-1 which is strong inhibitor of angiogenesis  ADDIN EN.CITE (Volpert et al. 2002).

1.6.6.5.	Id proteins, tumour invasion and metastasis
Tumour progression involves invasion of cancer cells into adjacent or distal regions, leading to metastasis of the original tumour.  This involves detachment of tumour cells, breakdown of the basement membrane and extracellular matrix surrounding the tumour, migration of tumour cells into the blood stream, attachment and further invasion of the tumour cells in the metastasis site (Ling et al. 2006).  MMPs represent a major protein family that regulates the degradation of basement membrane and remodelling of extra cellular matrix (ECM) (Egeblad et al. 2002).  The members of this family have been found to be overexpressed in many cancers  ADDIN EN.CITE (Shiomi et al. 2003; Gu et al. 2005; Ogawa et al. 2005). This was believed to facilitate the breakdown of the basement membrane and the ECM so that the cancer cells could infiltrate through and invade the adjacent tissue (Ling et al. 2006). 
High levels of Id1 was reported to be associated with invasiveness and disease progression in endometrial carcinoma (Takai et al. 2001) and in most aggressive breast cancer cell lines and primary tumours (Lin et al. 2000). Id1 has been shown to be a component of the metastasis signature in human breast cancer and its overexpression can drive metastasis in a breast cancer cell line injected into animals  ADDIN EN.CITE (Fong et al. 2003).   
In a murine non invasive mammary epithelial cell line, over expression of Id has been shown to activate the expression of gelatinase, a MMP enzyme, followed by  invasiveness of cells evidenced by the ability of these otherwise, to invade the basement membrane  ADDIN EN.CITE (Desprez et al. 1998).  Inversely the reduction of Id1 levels using an antisense slows cell-proliferation, facilitates differentiation and inhibits invasiveness of a malignant cell line  ADDIN EN.CITE (Fong et al. 2003). Moreover, it resulted in down regulation of MTI-MMP protein expression and tumour metastasis in xenografts ADDIN EN.CITE (Fong et al. 2003). These data suggest that Id1 positively regulate tumour invasiveness through upregulation of the MMP proteins (Ling et al. 2006).

1.6.7.	Ids and other genes involved in cancer

1.6.7.1.	Oncogenes
N-MYC has been shown to upregulate Id2 in Neuroblastoma.  The primary event in this pathway is amplification and expression of N-MYC oncogene which will bind to Id2 promoter and activates its transcription.  As a result Id2 will accumulate in the cells at levels that are sufficient for inactivation of RB pathway, thus cell proliferation  ADDIN EN.CITE (Lasorella et al. 2000; Raetz et al. 2003). Elevation of Id2 by MYC is essential for the ability of MYC to overcome RB mediated cell-cycle arrest and transform mouse fibroblast in cooperation with RAS  ADDIN EN.CITE (Lasorella et al. 2000).  Id1 and Id3 have also been identified as downstream targets of MYC.  Induction of Id1 by MYC appears to be required for breast cancer cells to enter S phase in culture  ADDIN EN.CITE (Swarbrick et al. 2005). 
A connection between MYC and Id3 has been identified in neural crest development using Xenopus laevis model.  MYC maintains neural crest progenitors in an immature state and Id3 overexpression can rescue the phonotype of C-MYC depleted embryos.  MYC binds to E box in Id3 promoter region  ADDIN EN.CITE (Light et al. 2005).  However some studies have created controversy about MYC/Id2 regulatory relation by reporting no correlation between Id2 expression and MYC oncogene amplification  ADDIN EN.CITE (Vandesompele et al. 2003).  
Activation of RAS oncogene signalling pathway leads to transcription activation of early growth response 1 (EGR1) which in turn induces the expression of Id1 (Lane 1992) and Id3  ADDIN EN.CITE (Bain et al. 2001).
In Ewing’s sarcomas it has been suggested that EWS-ETS (chimeric proteins) induce Id2 by activating its promoter directly  ADDIN EN.CITE (Fukuma et al. 2003).  Transduction of EWS-ETS into fibrosarcoma cells, resulted in the transcriptional upregulation of Id2  ADDIN EN.CITE (Nishimori et al. 2002).  
Latent membrane protein 1 (LMP1), the Epstein-Barr virus oncoprotein will induce expression of Id1 and Id3 which in turn will downregulate p27 in order to induce fibroblast transformation and oncogenesis  ADDIN EN.CITE (Everly et al. 2004).  

1.6.7.2.	Tumour suppressor genes
One of best documented  tumour suppressor pathways that Id proteins are involved in Id2/RB/E2F in which Id2 promotes proliferation through antagonizing pRB which in turn releases E2F to activate cell cycle progression factors (see section 1.6.3.1).
Id proteins also inhibit RB indirectly by inhibiting tumour suppressor CDKI factors p16, p21 and p27, which normally work in favour of cell cycle arrest by stopping CDKs to phophorylate RB (see section 1.6.3.2).
Another reported tumour suppressor inhibited by Id is Brca1, which is regulated by Id4 who decreases Brca1 expression and enhances tumorigenisity of breast cancer cells.  The mechanism of this regulation is not clear  ADDIN EN.CITE (Beger et al. 2001).




An Oncogene, by definition is a gene that undergone a genetic alteration that has  enabled it to transform normal cells into autonomously proliferating neoplastic cells (Perk et al. 2005).  Experiments examining Ids for these alterations are limited, and no mutations were found a couple of efforts to sequence Id1 and Id3 in malignant melanoma and ovarian tumors respectively  ADDIN EN.CITE (Arnold et al. 2001; Casula et al. 2003).  These results indicate that Id genes are not common oncogenes.  However in many tumors overexpression of Ids are mediated by well established oncogenes and also their overexpression influence important oncogenic pathways  ADDIN EN.CITE (Lasorella et al. 2001; Perk et al. 2005). 
In addition to the evidences of oncogenic properties of Ids, that has been discussed so far in this review, there are few evidences for these proteins ability to affect the state of tumors directly in vivo.  The best example to date probably is the formation of aggressive thymic lymphoma in transgenic mice after targeted expression of Id1 and Id2 in their thymocytes, which rapidly killed the mouse. It suggested that over expression of Id could be sufficient for transformation  ADDIN EN.CITE (Kim et al. 1999; Morrow et al. 1999).  The other example is generation of benign intestinal adenoma following expression of Id1 in intestinal epithelial cells (Wice et al. 1998). 









Small Cell Lung Cancer is an extremely aggressive pulmonary tumour that contribute to 20% of all lung tumours, and is fatal in most cases despite the best measurements available.  The underlying genetic alteration in this tumour is not still clear and there is not an efficient early diagnosis method available.  Finding new possible molecular genetic mechanisms involved in pathogenesis of SCLC  is crucial before any considerable changes could be made in treatment of this cancer.  
Id proteins have all the necessary properties to facilitate tumourigenesis.  However there are still a lot of questions about the exact role of Ids in carcinogenesis.  In order to use Id proteins as possible therapeutic targets in many cancers, these questions need to be answered.  One way is to examine the role of these proteins in new malignancy models in hope to open new windows toward finding new mechanisms or pathways that might involve these multi function proteins.   




Id proteins are over-expressed in SCLC cell lines and tissue sections and their expression is correlated with patient’s survival.

In the first part of this study the author has tried to test the hypothesis by designing experiments in order to answer following questions:
	Is Id1 over-expressed in a wider range of SCLC cell lines and tissue sections?
	What is the status of other Id family members, Id2, Id3 and Id4 in SCLC?
	Is there any correlation between Id expression and survival period of the patients after diagnosis?





































Preliminary data using a differential display technique, showed Id1 mRNA to be differentially expressed in malignant SCLC cell line Lu-165 compared to normal bronchial epithelial cell line, Beas-2b.  Following this observation, the first part of this study was designed to explore the expression of Id1 protein and other Ids (Id2, 3 and 4) in a wider range of SCLC cell lines and tissue section and thereafter to investigate any correlation between the expression of these proteins and the length of survival in patients after diagnosis of SCLC.  The main methods used in this section were Westernbloting and immunohistochemistry (IHC).
IHC is a technique that uses antigen-antibody bonding to determine presence/expression of a particular protein within a tissue section or cells.  It follows the same principals as other immunoassays such as Westernblot and radioimmunoassay but makes the reaction in situ, enabling investigators to observe the expression of a protein within its tissue localization and also inside cells.  This technique was introducded by Albert H. Coons in 1942 (Coons et al. 1950) who was the first to label an antibody with a fluerescednt dye and use it to detect protein expression within a tissue section. Ever since, the technique has developed greatly employing different methods that although follow the same basis of antigen-antibody reaction, aim for giving more sensitivity to the detection system. Most of antibodies used in all methods are IgG (Polak 2003).  
In an IHC reaction, a series of antibodies the number of which depend on the method used, are applied to the tissue. The first or primary antibody binds to the antigen in the tissue. In direct or one-step method the reaction ends here and the reaction site is detected depending on the labelling system used.  This could be a fluorescent dye detected by fluorescent microscope, enzymes creating specific colour, or biotin.  The latter would need an additional reaction with labelled avidin.  Alternatively the primary antibody can act as an antigen for the secondary antibody in indirect or two-step method.  The secondary antibody which is labelled, is sensitive to the immunoglobulin of the species that gave the first antibody. The sensitivity of two-layer method is higher than one-step method because there is at least two binding site on primary antibody, each can attach to one molecule of secondary antibody.  Moreover this second layer is usually made hyperimmune and of very high avidity.   The technique’s sensitivity increases 100-1000 times in three-layer method in which the third layer is an anti-peroxidase immunoglobulin.  The reagents in one of the layers bares a label to make the immunoreactions site recognisable for the detection reagent that is added to the reaction at the final step (Polak 2003).  
The method used in this study was Dako’s EnVision method, using reagents provided by the manufacturer.  This method is a two-layer method, that achieves sensitivity up to the level of three-step labelled avidin method by using secondary antibodies conjugated to polymers that carry a large number of peroxidise or alkaline phosphatase molecules (Polak 2003). The details of the method used are explained in section 2.2.5 of methods.  
IHC over decades has evolved from a research method into a technique widely used as a major tool of diagnostic surgical pathology.  At the beginning the aim for employing this method was limited to determining the “presence” of a particular protein, usually a tumour specific marker.  With new advances in the technique and new antibodies available, IHC’s job has shifted towards discovery of molecular biology and regulatory proteins involved in tumour/disease development or progress, especially testing prognostic markers in neoplastic diseases.  In this regards the question is no longer the mere presence of a protein, but the quantity of it as well.  Usually the term “semi-quantitative” is preferred for relative measurements reported from IHC, carrying the element of subjective judgement of the observer within the word as opposed to absolute quantitative methods such as enzyme-linked immunosorbant assay that is a technique with exact basis of IHC performed on serum instead of tissue (Taylor et al. 2006).   Several efforts have been made towards establishing quantitative IHC.  These include standardization of pre-analytical, analytical and post-analytical factors and methods that can affect the end-result of the test.  These cover all elements from the second the tissue is removed from the patient including handling and fixation methods, to antigen retrieval, reagents validation and controls and finally reading, scoring and quantification methods (Taylor et al. 2006).   One of the most important parts of this standardization is assessment and scoring method.  Depending on the aim of the study extent or intensity or both might have to be assessed.  Usually positive controls, internal or external, are used to standardize the intensity of staining.  The extent of staining regardless of intensity is assessed by counting the number of positive cells in at least 1000 cells.  Some investigators add these two values while others multiply the two to get the final score.  The most reliable way is to use relative values comparing to a control. In practice any scoring system has been proven to give statistically significant correlation with clinical outcomes, given the observer was an experienced person in the area. This is another meaning of semi-quantitative assessment.  In any case what is important is to report in details the scoring criteria for each investigation, giving the chance to other investigators to reproduce the same system in order to get comparable results  ADDIN EN.CITE (Seidal et al. 2001; Walker 2006).
Recently the notion of automated quantitative analysis has found its way into a lot of diagnostic laboratories.  These methods use computerized image analysis systems and in many cases have produced more accurate means of quantification for some antigens.  These methods eliminate the inter-observer differences and also subjective judgmental faults including tiredness or visual assessment variation between slides and will give more reliable quantitative measurement of the stain.  However the investigator still is influential after image acquisition in terms of setting the reading and measurement criteria for the software used  ADDIN EN.CITE (Taylor et al. 2006; Walker 2006).







10 malignant SCLC cell lines alongside one normal epithelial cell line were used in this study.  The malignant SCLC cell lines include: NCI-H69 (Gazdar et al. 1980), NCI-H82, NCI-H417 (Gazdar et al. 1985), Lu-165 (Terasaki et al. 1994), NCI-H 345, NCI-H526 (Carney et al. 1985), U2020 (Mellstrom et al. 1987), COR-L47, COR-L88 (Carritt et al. 1992) and GLC-19 (Berendsen et al. 1988) all established and described previously as SCLC cell lines in corresponding references.  The normal epithelial cell line Beas-2b is a human bronchial epithelial cell line immortalized by infection with an adeno- 12-SV40 hybrid virus (Reddel et al. 1988). 
All reagents, media composition and materials are detailed in Appendix 3.










Cell lines NCI-H69, NCI-H82, NCI-H417, Lu-165, NCI-H 345, NCI-H526, COR-L47, COR-L88 and GLC-19 grow in floated cell aggregation.  To subculture these cell lines the following steps were taken.
Flasks containing growing cells were removed from the incubator. Media containing cells were removed from the flasks and transferred into 25 ml universal tubes that were centrifuged for 2 minutes at 900 rounds per minute (rpm) following removal of the supernatant media that was discarded.  The cells then were resuspended in 2 ml fresh media and disaggregated by gentle pipetting to avoid shearing the cells. Finally each 1 ml was transferred to a new flask containing appropriate amount of fresh media.
2.2.2.2.2.	Adherent cells
Beas-2b
This cell line is an adherent cell line therefore in order to sub-culture trypsinizing is necessary.  First the culture media was removed from the flask and the cells were washed in PBS once.  Cells were then incubated with Trypsin/EDTA (TE) at 3ml/9cm2 surface at 37oC for 2 minutes or until cells were rounded and detached from the surface of the flask. At this point cells were removed from the incubator and T/E was inactivated using an equal volume of culture medium. The media T/E mixture containing cells were removed from the flask and transferred into universal tubes and centrifuged for 2 minutes at 900 rpm followed by removing the supernatant that was discarded. The cell pallet was resuspended in 2 ml fresh culture media and divided into 2 X 1 ml transferred into new flasks containing appropriate amount of fresh media. 

U2020
This cell line also was adherent, but was not firmly attached to the plate (psudo-adherent).  Therefore there was no need for trypsinising the cells in order to detach them.  After removing the culture media, cells were dislodged from the flask by adding PBS and pipetting the solution for a few times. PBS/cell mixture was centrifuged in universal tubes for 2 minutes at 900 rpm.  The cell pallet was resuspended in 2 ml fresh culture media and divided into 2 X 1 ml transferred into new flasks containing appropriate amount of fresh media. 

2.2.2.3.	Cryopreservation of SCLC cell lines
In order to ensure having a stock of cells, cells are cryopreserved. Cryomedium was prepared by adding 1 ml of DMSO to each 9ml of routine growth media to make a 10% solution. Cells were harvested with appropriate method depending on their growth type (suspension or adherent cells) and then resuspended in 5 ml of growth medium. From cell suspension, 50µl was placed in a 1.5 ml microtube.  The cells were disaggregated into single cells by pipetting. In order to quantify viable cells, 50µl of Trypan blue was added to the cell suspension and mixed, then placed on haemocytometer. A volume of cell suspention containing n x 106 viable cells was transferred to another universal tube and centrifuged again at 110xg for 2 minutes and the supernatant was removed and discarded. Cryomedium was added to the cell pellet to make 1 x 106 cells per ml dilution and 1 ml was pipetted into each cryotube (Nunc) that were labelled with cell line name, number of cells, passage number, date and researcher’s name.  Cryotubes were placed in cryobox that was already filled with isopropanol (IPA) in -80oC freezer before being transferred into liquid nitrogen.  Having the property to cool down slowly (-1oC per minute), IPA allowed the cryomedium to freeze gradually to inhibit formation of ice crystals within cells during cryostasis and cell damage when thawing out. Cryotubes were transferred to liquid nitrogen the following day.

2.2.2.4.	Recovery of cryopreserved cells
Cryogenically preserved cells were thawed by removal of cryotubes from liquid nitrogen and placing in a 37oC water bath to thaw. Cells were mixed with 10ml of routine cell medium in a universal tube and centrifuged at 900rpm for 2 minutes; the supernatant was removed and discarded. Cell pellets were resuspended in 10 ml of routine media and transferred into 25 cm2 filter cap flasks.

2.2.3.	Protein extraction and assessment
2.2.3.1.	Protein extraction
Cells were harvested from culture flask with appropriate method to the growth type.  The cell concentration was determined following trypan-blue stain using a haemocytometer. Volumes of cell suspension containing n x 107 cells were transferred into new universal tube and centrifuged on 900 rpm for 2 minutes. The cell pellet was resuspended in n x 125µl cell of lysis reagent (celLytic-M, Sigma) and mixed well by pipetting or vortexing. The mixture was transferred into 1.5 microtube and incubated at room temperature for 15 minutes while agitated, then centrifuged at 13000 rpm for 15 minutes. The protein containing supernatant is transferred to new microtube for protein concentration determination.

2.2.3.2.	Protein assay
To determine protein concentration of the lysate Bio-Rad protein assay system (BIO-RAD) was used.  This system employs a dye-binding assay based on the different color change of a dye in response to various concentration of protein.  The basis of this assay initiated from Bradford’s observation that the absorbance maximum for an acidic solution of Coomassie Brilliant Blue shifts from 465 nm to 595 when binding to protein occurs (Bradford 1976; Sedmak et al. 1977).  Dye reagent concentrate was diluted 5 times by adding distilled water to the stock solution and filtered through Whatman filter paper. Dilution series of the protein standard (Sigma, 0.4 mg/ml) was prepared to contain 400, 300, 200, 150, 100, 75, 50, 25 µg/µl concentrations of protein respectively with final volume of 50µl in labelled microtubes. A blank sample contatining 50µl of distilled water was also prepared.  From each lysate sample to be measured, 5µl was added to 45µl of distilled water to make a 1/10 dilution in labelled microtube. From filtered dye reagent, 1 ml was added to each titrating tube and also the lysate samples and left to develop colour at room temperature for 5 – 60 minutes. The colour absorption for each titration tube and lysate sample was measured using spectrophotometer at 595 nm wave length. Using the known values of standard protein concentration of titration samples and corresponding absorption for each concentration a standard curve was drawn in spread sheet and corresponding equation for the standard curve was calculated.  The unknown concentration of protein lysates was calculated by putting the absorption value of lysate samples into the equation.

2.2.4.	Polyacrylamide gel electrophoresis and immunobloting

Polyacrylamide gel electrophoresis separates molecules including proteins in complex mixtures according to size and electrostatic charge.  During electrophoresis there is an intricate reaction between samples, gel matrix buffers and electrical charge resulting in separate bands of individual molecules  ADDIN EN.CITE (Ornstein 1964; McLellan 1982).  The fractionized proteins on the gel is transferred to a nitrocellulose membrane using an electrophoretic transfer cell system. Finally the investigated protein is probed by administration of primary and secondary antibodies and visualised using a chemoluminescence reagent and exposure to Kodak film.
All reagents, media composition and materials are detailed in Appendix 3.

2.2.4.1.	Protein separation by SDS-PAGE
Protein was extracted from each cell line using celLytic-M, and the protein concentration for  each lysate was measured using Bio-Rad  protein assay system.  Samples were prepared by mixing equal amounts (v-v) of double strength sample loading buffer and lysate containing 50 µg protein extract of each cell line and heated to 99oC for 10 minutes.  The samples were run and separated on 15% polyacrylamide gel in a Mini-Protein 3 Cell system (BIO-RAD) in 500 ml of 1x electrophoresis buffer alongside Prosive Colour Protein marker (Lonza) estimate protein size.  The gel was run at 200V for 30-45 minutes depending upon the rate of separation.  

2.2.4.2.	Transfer of proteins from SDS-Gel to nitrocellulose membrane
For transfer process, Mini Trans-Blot Electrophoretic Transfer Cell (BIO-RAD) was used.
Two filter pads, six sheets of Whatman 3mm filter paper and one nitrocellulose membrane were cut to the size of gel and soaked in 1 x transfer buffer for at least 15 minutes.  The SDS-gel containing the fractionized protein was soaked in 1 x transfer buffer for at least 15 minutes. Starting from anode side of the electrode, the transfer sandwich was assembled with three Whatman filter sheets placed on the top of one filter pad, followed by SDS-gel, nitrocellulose membrane, three whatman filter sheets and finally one filter pad at the cathode electrode side. Using a small roller, air bubbles between SDS-gel and membrane were squeezed out. Transfer of proteins from gel to membrane took place at 4oC for 2 hours at 100V.  At the end of transfer process, the transfer sandwich was disassembled, the membrane was stained with 10% Ponceau S solution (Sigma) for 5 minutes and destained with 0.05% T-TBS.   The gel was stained in Coomassie Blue stain (Severn Biotech Ltd) overnight, destained in distilled water over following night and dried on Whatman filter paper in a gel drier for future reference.  Both staining processes were conducted to assess the efficiency of transfer from gel to membrane.

2.2.4.3.	Immunoblotting procedure for detection of protein expression
Nitrocellulose membrane containing fractionized proteins was incubated in 5% protoblock for 1 hour at room temperature to prevent non-specific binding of primary antibody. Primary antibody (Rabbit anti-human Id1, Id2, Id3 or Id4 polyclonal antibody, Santa Cruz) was mixed with 5% protoblock at a 1:100 ratio (v/v). The membrane was incubated in this mixture overnight at 4oC.  The following day, membrane was washed 3 x 15 minutes in 0.05% T-TBS, then incubated in secondary antibody (swine anti-rabbit horseradish peroxidase-conjugated, HRP, immunoglobulin, Dako) at a 1:1000 dilution in 5% protoblock for 1 hour at room temperature.  Then the membrane was washed 3 x 15 minutes in 0.05% T-TBS.  Electro Chemical Luminescence systemTM (ECL, Amersham) was used for visualizing probed antigens on the membrane.  The ECL detecting solution was prepared by mixing reagents 1 and 2 at 1:1 ratio.  This solution was placed on the protein face of membrane for 1 minute.  Excess reagents were drained and membrane was wrapped in saran wrap, and exposed to Kodak films in a film cassette, from 1 minute to 15 minutes. The film then developed and the image was fixed in darkroom.

2.2.4.4.	Immunoblotting to detect β-actin protein expression
In order to normalize any variation in protein loading among different samples, the expression of constitutively expressed protein β-actin was detected on the same membrane that was immunoblotted for the main antibody.  Membrane was washed 2 x 15 minutes in T-TBS to remove ECL solution, then bloked in 5% protoblock for 1 hour in room temperature.  The immunoblotting procedure was the same as for the main antibody except for the shorter incubation periods for primary and secondary antibody, each 30 minutes at room temperature, and shorter T-TBS washing steps, 3 x 10 minutes.  The primary antibody, mouse anti-β-actin monoclonal antibody (Sigma), was diluted into 1:5000 and the secondary antibody, rabbit anti-mouse HRP immunoglobulin (Dako), was used at 1:1000 dilution. The same ECL detection system was used but the exposure time to the film was reduced to 10 second to 1 minute.

2.2.4.5.	Calculation of relative expression  value of each protein 
The raw expression of Id protein and β-actin in each cell line sample was quantified by measuring the area under the corresponding curve created by Alphamager 2000 (AlphaEase TM) program, attached to the transilluminator.  For each cell line, the raw expression value (EV) of protein was normalized to β-actin expression using this formula: 
EV of Id protein = EV of Id protein ÷ EV of β-actin
In each experiment, normal epithelial cell line Beas-2b was used as the control. If the protein expression in this cell line was zero, cell line with the lowest expression was considered as control. The relative expression values of all the other samples were calculated by dividing their expression value by that of the control.  
2.2.5.	Immunohistochemisry
26 pairs of formalin fixed and paraffin wax embedded (FFPE) human SCLC tissues and the corresponding adjacent normal epithelial sections from the same patient, as well as 100 FFPE biopsy samples were obtained from the archive of Royal Liverpool Hospital in accordance with ethical regulations of Liverpool University Ethics Committee and Medical Research Council guidelines.  The histopathology diagnosis of SCLC for the samples was verified by a consultant lung pathologist according to haematoxylin and eosin (H & E) stained slides corresponding to each paraffin block.
All reagents, media composition and materials are detailed in Appendix 3.

2.2.5.1.	Preparation of aminopropyltriethanoxysilane (APES) coated slides.
In order to prevent sections floating off the slides during high temperature treatment, twin frosted microscopic slides were coated with APES before putting the sections on them.  This is performed by incubation of slides in acetone for 10 minutes, followed by 2% APES solution for 5 minutes.  Then the slides were washed in two rinses of absolute ethanol.  The final step was to blot off any excess ethanol and dried in 60oC oven for 30 minutes or until dry.  Once completely dry, slides were transferred back into the original slide box. 

2.2.5.2.	Tissue sectioning
A water bath was filled with distilled water and heated to 60oC.  The microtome was cleaned with xylene and a new disposable blade was fitted to the machine.  The FFPE tissue blocks were pre-cooled on ice.  Tissue sections were cut into 4µm thick sections, which were flattened on water surface, then mounted onto labelled twin frosted microscopic slides.  The slides were dried overnight at 55oC. From each FFPE block, at least 4 slides were prepared, each labelled for one Id antibody ( Id1, 2, 3 and 4).

2.2.5.3.	Immunohistochemistry 
In this study, EnVision detection reagents and instruction  (DAKO Ltd) was used. In summary, sections mounted on slides were loaded on metal slide trays, dewaxed in xylene  for 2 x 3.5 minutes following by rinsing in 100% IMS (Industrial methylated Spirit) for 2 x 30 seconds.  In order to block endogenous  peroxidase, the slides were incubated in hydrogen peroxide-methanol solution for 12 minutes at room temperature. Then the slides were rinsed in running tap water and deionised water each for at least 30 seconds.
Antigen retrieval was conducted by microwaving tissue sections for 25 minutes in 10mM Tris-EDTA buffer (PH 9.0) at full power, then standing for 5 minutes, followed by rinsing in distilled water for at least 30 seconds to remove excess buffer.  For antibody application slides were transferred to special cover plates (Shandon UK) and transferred to sequenza casstte (Shandon UK).  Before application of primary antibody, sections were washed with Tris-buffered Salin (TBS) by adding the buffer to the top container of cover slips, allowing it to flow through over a period of 4 minutes.
In the next step, in order to block non-specific binding of primary antibody, 100 µl of 5% Bovine Serum Albumin in TBS (BSA/TBS) was added to each section and left to incubate at RT for 10 minutes.  Sections were removed from sequenza cassette and put in flat position on a flat immunohistochemistry tray.
Primary antibody (rabbit polycolonal anti human Id1, 2, 3 or 4 antibody, Santa Cruz), was mixed in BSA/TBS at v/v ratio of 1/100 and 200µl of this mixture was pippetted onto each section.  The slides were incubated at 4oC overnight.  The sections were then transferred back onto sequenza cassette and washed with TBS for 2 x 4 minutes.  Sections were incubated in 100µl of anti-rabbit horse radish peroxidase (HRP) conjugated polymer (Dako Ltd, Ely, UK) for 30 minutes at RT followed by one washing step by TBS for 4 minutes.  
To visualise the antibody labelled protein, 3,3’ diaminobenzidine tetrahydochlorate, DAB, (Dako) was mixed with Chromogen substrate (Dako) at ratio of 1:50, then 100µl of the mixture was applied to each slide and incubated for 10 minutes at RT.  DAB was washed off slides by distilled water for 4 minutes.
Slides were removed from sequenza cassette, transferred to metal slide racks and washed in runnig tap water for at least 2 minutes. Sections were counterstained in Haematoxylin solution, washed briefly in running tap water, cleared in 0.5% acid-alcohol, and finally incubated in Scott’s Tap Water Blueing agent.  After washing thoroughly in running tap water, the final step was to dehydrate the sections in rising concentrations of 80% to 95% of IMS.  The sections were cleared of any remaining water by going through 3 changes of xylene, then mounted in DPX synthetic resin and covered with coverslips.
Sections stained for each antibody were observed and scored for protein expression according to following system.

2.2.5.4.	Criteria used for scoring immunohistochemical stained tissue sections 
In samples containing normal bronchial epithelium tissue sections, where there was more than one airway, the largest in the section was considered to be assessed for staining.  Attempt was made to score the most “normal” part of the epithelium, i.e. hyperplasia or squamous metaplasia was avoided as much as possible and the edges of the section where it might have dried out or the antibody might have not reached the cells were ignored. Both cytoplasm and nuclei were scored separately.  
In malignant counterparts, the homogenously stained part of the section was considered to be scored, i.e. the edges of the section with no-antibody appearance or very high back ground (dry parts) wasn’t considered.  Again, both cytoplasm and nuclei was scored separately.  
To evaluate intensity of staining approximately 10 fields at 40 magnification were counted and scored as follows:
0 = no positive staining observed.
1 = predominantly weak staining observed.
2 = predominantly moderate staining observed.
3 = predominantly strong staining observed.
To standardize the intensity score, the intensity of a positive control sample, a malignant prostate carcinoma sample was scored as intermediate and used as the constant comparison reference throughout the scoring.  This control block was stained in each set of experiment alongside main samples.  Any intensity above this control was considered as strong or 3, while lower intensities was scored as weak or score 1.
To evaluate percentage of staining regardless of intensity, approximately 10 fields at 40 magnificattion were counted, at least 100 cells in each field and scored as follows:       	
	0 = less than 10% of the cells staining positively.
	1 = 10-29% of the cells staining positively.
2 = 30-49% of the cells staining positively.
3 = 50-79% of the cells staining positively.
4 = 80-100% of the cells staining positively.
The scores from both intensity and percentage were then multiplied to give an index which was scored as follows:
	0 = negative
1 = index of 1-4
2 = index of 5-8
3 = index of 9-12
This was considered as the final score and was used for statistical analysis as follows:
0 = negative expression of the protein
1 = weak expression of the protein
2 = moderate expression of the protein
3 = strong expression of the protein.
Scoring was repeated by three persons including one consultant lung pathologist.  The inter-observer diversity was less than 10% that was considered as not significant.   

2.2.6.	Statistical methods
To test the significance of expression difference between SCLC malignant sections and corresponding adjacent normal epithelium sections the Wilcoxon Signed Rank test was used and ρ values < 0.05 were considered as significant.





2.3.2.	Expression of Id proteins in SCLC cell lines and normal epithelial cell line

To determine expression of four Id proteins in SCLC cell lines, SDS-PAGE After performing three different Westernblot experiments for each protein, the average of relative expression values of Id1, Id2, Id3 and Id4 proteins for each malignant cell line  was compared to one normal epithelial cell line (Beas-2b).      In case of Id1 protein, 8 out of 10 malignant cell lines showed higher expressions of the protein comparing to Beas-2b cell line. The relative expression in these 8 cell lines was 1.7 – 21.4 fold higher than normal epithelial cell line.  
Id2 protein was negative in all three experiments in normal epithelial cell line, when the lowest value, the one of GLC-19 was set to 1, 8 out of 10 malignant cell lines showed expression values of 1 to 14.  
Expression value of Id3 protein was very low or negative in Beas-2b in different blots. Neverthless, when the average of its expression value was calculated and compared to the average relative expression values of 10 malignant cell lines, 9 out of 10 SCLC cell lines were expressing higher values of Id3 protein than Beas-2b, with 1.7 to 12.1 folds.  









































































Figure 2.2: Graphic demonstration of relative expression levels of Id1 (A), Id2 (B) and Id3 (C) protein expression in 10 SCLC cell lines and normal epithelial cell line, Beas-2b.  Each expression value is average of 3 separate experiments. Id4 level wasn’t measurable and comparable.  (Kamalian et al. 2008)
2.3.3.	Expression of Id family proteins in normal lung and malignant SCLC tissue sections

To compare the expression of four Id proteins in normal bronchial epithelium and malignant SCLC tissue sections, 26 pairs of malignant/adjacent normal epithelial tissue section from the same patient were tested using Immunohistochemistry.  Four sets of experiments were performed using antibodies to Id1, Id2, Id3 and Id4.  In each sample, the expression of corresponding Id protein was quantified according to scoring system explained in section 2.2.5.4.  Nuclear and cytoplasmic staining was appraised separately for each protein.  The final scores were tested by Wilcoxon Signed Rank test to determine the significance of the expression difference between normal and malignant tissues.  
Id1, Id3 and Id4 exhibited both nuclear and cytoplasmic staining while Id2 expression was predominantly limited to the cytoplasm of the malignant cells.  Id1 staining was more localized in the cytoplasm of malignant cells although expression of the protein was also detected in the nuclei.  Malignant SCLC cells showed Id3 expression in both nuclei and cytoplasm, with nuclei demonstrating more intense staining when comparing to the cytoplasm.  Although both nuclei and cytoplasm of the malignant cells expressed the Id4 protein, with nuclear staining being slightly darker than that of the cytoplasm, the general trend for intensity score was weak to moderate.  


















Table 2.1.  Immunohistochemical detection of the expression of Id proteins in SCLC and their normal counterparts
                           Malignant to Normal                   	Over expression	Same expression	Under expression	ρ value*
            Id protein				
Id1	CytoplasmNo. (%)	14 (54%)	10 (38%)	2 (8%)	<0.005
	NucleiNo. (%)	0 (0%)	3 (12%)	23 (88%)	< 0.001
Id2	CytoplasmNo. (%)	21(81%)	4 (15%)	1(4%)	<0.001
	NucleiNo. (%)	3(11%)	15 (58%)	8(31%)	0.675
Id3	CytoplasmNo. (%)	23 (88%)	2 (8%)	1 (4%)	< 0.001
	NucleiNo. (%)	23 (88%)	3 (12%)	0(0%)	< 0.001
Id4	CytoplasmNo. (%)	18 (69%)	8 (31%)	0 (0%)	< 0.001
	NucleiNo. (%)	18 (69%)	6 (23%)	2 (8%)	< 0.001

Note:   Altogether 26 pairs of tissue samples were stained. Each pair consisted of a SCLC tumour section and a sample of normal adjacent bronchus epithelium from the same patient. 

























Figure 2.3:  Immunohistochemical staining of Id family proteins Id1 (A), Id2 (B), Id3 (C) and Id4 (D) in malignant small cell lung carcinoma tissues (1) and in the corresponding normal bronchial marginal epithelium form the same patient (2). The negative control (3) in each set of experiments was obtained by blocking the staining with different recombinant Id proteins (Kamalian et al. 2008).


2.3.4.	Expression of Id proteins in large numbers of SCLC biopsy samples. 

Immunohistochemical staining was also done on an archival set of a large number of SCLC biopsy samples to further examine the expression status of the four Id proteins in carcinomas. Similar to that observed in the 26 pairs of lung tissues, Id1 expression in the SCLC biopsy samples was mostly cytoplasmic and Id2 expression in nuclei was negative. In the cytoplasm, 69 of 91 (76%) cases exhibited positive Id1 staining, and 82 of 91 (90%) cases exhibited positive Id2 staining. Staining was done on 89 and 93 cases with the antibodies against Id3 and Id4, respectively. In cytoplasm, 65 (73%) and 77 (83%) were positive, most of which (47 of 65 and 63 of 77, respectively) were weakly stained. In nuclei, 80 (90%) and 77 (83%) were positive, most of which (68 of 80 and 52 of 77, respectively) were moderately to strongly stained.




























Figure 2.4:  Immunohistochemical examination of the expression of different Id proteins in SCLC biopsy samples. A) Nuclear expression of Id proteins. B) Cytoplasmic expression of Id-proteins. Consistent with staining results from the main study, Id1and Id2 showed strong expression in the cytoplasm expression, while Id3 and Id4 were highly expressed in the nuclei (Kamalian et al. 2008).

2.3.5.	Correlation between Id protein expression and survival period of patients

To assess the relationship between increased expression of each Id protein and patient survival, 90-100 FFPE biopsy samples with diagnosis of SCLC were stained for each Id protein using immunohistochemistry technique and scored using the same scoring system for the main study.  These biopsy samples were diagnostic samples before any treatment had started for the patient.  According to their staining scores, cases were divided into two groups of “moderate to strong” and “negative or weak” expression groups for each Id protein, considering nuclear and cytoplasmic staining separately.  The length of time the patient stayed alive after diagnosis of SCLC was examined against the Id protein expression level at the time of diagnosis using Kaplan-Meier survival analysis.  
Among four Id proteins, Id2 cytoplasmic expression was found to have a positive correlation with patient survival, i.e. moderate to strong expression of Id2 was correlated with longer patient survival, with median term of 10 months comparing to 3 months in negative or low expression group.  This correlation was significant with ρ value of 0.001(Figure 5B).    












































Table 2.2:  Correlation of the expression of different Id proteins to patient’s survival

Survival Analysis Id Protein	Median Survival in Group 1* (Months)	Median Survival in Group 2* (Months)	Kaplan Meier Analysis: ρ value
Id1NucleiCytoplasmId2NucleiCytoplasmId3NucleiCytoplasmId4NucleiCytoplasm	-----**7.0 (+/_ 1.8)-----**3.0 (+/_ 0.8)4.0 (+/_2.7)6.0 (+/_1.7)5.0 (+/_ 1.3)6.0 (+/_ 1.9)	-----**4.0 (+/_  3.3)-----**10.0(+/_0.7)7.0 (+/_1.6)9.0 (+/_4.2)6.0 (+/_2.6)4.0 (+/_2.8)	-----**o.597-----**0.0010.3830.8770.5960.256

* Group 1 represents the cases with negative/weak staining; Group 2 represents moderate/strong staining.






























In contrast to the extensive studies of Id proteins in other cancers, their possible involvement in the development and metastasis of SCLC has not been previously investigated.  The first part of this study was based on preliminary data suggesting overexpression of the Id1 protein in SCLC cell line Lu-165, when compared to normal bronchial epithelial cell line Beas-2b, using a differential display technique.  The aim of this part of study was to investigate the expression of four Id proteins in a wider range of samples, including 10 SCLC cell lines and 26 pairs of tissue sections, with the hypothesis that Id family proteins might be dys-regulated in SCLC and hence have a significant role in the tumourigenesis of this malignancy.
Using Western blot technique, it was demonstrated that Id1 protein was over-expressed in eight SCLC cell lines out of 10 in comparison to normal epithelial cell line.  The increased level of Id1 was ranged from 1.7 to 21.4 fold relative to Beas-2b level, when the latter was set to unit one.  Furthermore, Id2 and Id3 also showed higher levels of expression in 8 and 9 out of 10 malignant SCLC cell lines respectively than normal Beas-2b cells, in which the expression of Id2 was not detected.  These results showed that malignant SCLC cells either increased their level of Id1 and Id3 or started to produce Id2.  Thus, the increased expression of these 3 proteins was associated with the malignant characteristics of the cells, indicating they might play some roles in the malignant transformation.  
Surgery is not considered a standard treatment for SCLC after diagnosis (Fox et al. 1973).  Hence archival samples of these tumours are usually not abundant.  However limited numbers of tumour tissue sections were obtained from the Royal Liverpool University Hospital archive.  From these cases 26 were confirmed to be typical SCLC; for each of which used in this study, a normal bronchial epithelial margin sample was taken from the same patient as control.  Pairing the samples provided an excellent resource to compare the expression of four Id protein between the malignant SCLC cells and their normal counterparts.  Using immunohistochemical staining, we found that expression of all four proteins was significantly increased in the cytoplasm of the malignant cells when compared to the normal epithelium.  Four Id proteins showed different patterns of nuclear expression. Whilst Id3 and Id4 were expressed in higher levels in the nuclei of the malignant cells, nuclear expression of Id2 was not statistically different. Although Id1 exhibited a lower staining score in the nuclei of SCLC cells, the total amount of this protein is generally up-regulated in the malignant cells, since Westernblot detected an increase of Id1 protein in the whole cell protein content.  These findings were consistent the differential display result which was in favour of Id protein overexpression in SCLC.
Immunohistochemical staining showed that Id1 protein within SCLC cells was localised mainly in the cytoplasm, as it does in some other cancer cells, such as prostate (Forootan et al. 2007).  The increased expression of Id1 in cytoplasm significantly correlated with the malignant property of pulmunary tissues. Conversely, it was observed that the expression of Id1 in the nuclei of the SCLC cells was reduced. Thus, not only the level of Id1 expression, but also the pattern of its distribution was associated with the malignant changes of the lung epithelial cells. Further investigation is needed to understand the biological significance of both the increased level and the changed distribution pattern of Id1 in malignant changes of the SCLC cells.  It has been reported that the localization of Id2 is different amongst different cancers.  In prostate cancer, Id2 is expressed in both cytoplasm and nuclei (Yuen et al. 2006). In pancreatic carcinoma, it expressed only in the cytoplasm  ADDIN EN.CITE (Maruyama et al. 1999). While in head and neck squamous cell carcinoma (Langlands et al. 2000) and cervical cancer  ADDIN EN.CITE (Schindl et al. 2001), its expression was confined to nuclei only.  In this work, it was found that Id2 is expressed predominantly in the cytoplasm of the SCLC cells. It is not clear whether the different distribution patterns observed in different types of cancers relate to the possible different roles played by increased Id2. Similar differences in distribution patterns amongst different cancer types have also been observed in Id3, which was cytoplasmic in prostate cancer (Yuen et al. 2006) but nuclear in head and neck squamous cell carcinoma (Langlands et al. 2000) and cervical cancer  ADDIN EN.CITE (Schindl et al. 2001). The results in this work showed that Id3 in both cytoplasm and nuclei of the SCLC cells was significantly increased and the intensity of nuclear expression appeared to be greater than that in cytoplasm, indicating large amount of Id3 protein was concentrated in nuclei where it probably functions as a cancer promoter. 
The location of Id4 in this study was stronger in the nuclei, similar to that reported for high grade prostate carcinoma (Yuen et al. 2006). It was noticeable that the expression of Id4 in most cases was either weak or moderate.  This observation plus the undetectable amount of this protein in Westernblot analysis, suggests that this protein might function with very small amounts within the malignant cells.   Previous investigations have always separated Id4 from other Id proteins in regarding its pattern of distribution and function during development.  For example during embryogenesis Id4 is selectively expressed in the nervous system while the other Ids are expressed in many peripheral tissues.  Moreover, distribution of Id1, Id2 and Id3 are often overlapping while that of Id4 is unique and unrelated to other Ids  ADDIN EN.CITE (Riechmann et al. 1994).  These findings suggest that perhaps the function of this protein is also different from other members of Id family.  Consistent with this assumption is that unlike other Id proteins, no correlation has been identified between Id4 expression and cell growth  ADDIN EN.CITE (Zebedee et al. 2001).  Therefore it is not surprising to find a different pattern of expression or function for Id4 in cancer studies. Such difference was reported in prostate cancer where Id4 was suggested to have a role in distant metastasis rather than tumourigenesis (Yuen et al. 2006).  Conversely, breast cancer studies have shown a correlation between hypermthylation of Id4 promoter region and aggressiveness of the tumour as well as patients’ better outcome.  These studies suggest a tumour suppressive role for Id4 in breast cancer  ADDIN EN.CITE (Umetani et al. 2005; Noetzel et al. 2008).  Between these two opposite roles for Id4 protein, it is more likely that in SCLC Id4 plays a tumourigenic rather than tumour suppressive role, since its expression is correlated with malignant phenotype.  Following the same trend as prostate cancer and considering the highly disseminative nature of SCLC, it can be speculated that Id4 might have a role in invasiveness of this cancer rather than tumour growth or proliferation, a role that has hardly been related to Id4  ADDIN EN.CITE (Zebedee et al. 2001).  
To investigate the correlation of Id protein dys-regulation and the SCLC patient’s survival after diagnosis a large number (n = 90-100) of biopsy samples of confirmed cases of SCLC was used.  The original 26 pairs of tissues were not used in the survival analysis because these tumours had been surgically removed, which is not the standard treatment of SCLC.  Assessment of the relationship between the Id protein status and patient survival showed that although Id1, Id3 and Id4 are all significantly over-expressed in SCLC, the increased expression levels are not significantly associated with the length of the patient survival (Table 2.2). However, cytoplasmic expression of Id2 does show a significantly (Table 2.2) positive correlation with patient’s survival (p = 0.001). When Id2 was negatively or weakly expressed in the cytoplasm of SCLC cells, the average patient survival was 3 months, whilst when moderately or strongly expressed, this was increased to 10 months. This result suggested that the increased cytoplasmic Id2 is a positive factor for patient survival. Immuno-staining also showed that no Id2 was detected in nuclei of SCLC cells in the biopsy samples, whereas in marginal bronchial epithelial cells, Id2 protein does present in nuclei (Table 2.1). It is possible that in SCLC cells, part of the increased cytoplasmic Id2 protein is achieved from the nucleus. 
Being a transcription factor, Id2 is only functional if it locates inside the nucleus where it can execute its regulatory effect on other HLH transcription factors and also on important molecules such as RB protein  ADDIN EN.CITE (Kurooka et al. 2005).  RB protein, one of the most important tumour suppressor factors within cells is mutated in more than 90% of SCLC cases (Osada et al. 2002). Its main function is to inhibit cells from hyper-proliferation by binding to E2F transcription factor, hence cell cycle arrest  ADDIN EN.CITE (Forgacs et al. 1998).  One anti proliferative mechanism applied by RB protein is to sequestrate Id2, thus inhibiting it from intervention with other transcription factors.  Inversely, when in excess Id2 can bind and inhibit RB protein resulting in cell proliferation  ADDIN EN.CITE (Lasorella et al. 2001).   At least two other important genetic changes of SCLC involve Id2 in their regulatory pathways.  One is MYC oncogene whose amplification has shown to up-regulate Id2 expression (Raetz et al. 2003).  MYC amplification has been detected in more than 80% of SCLC tumours (Wistuba et al. 2001).  It is speculated that MYC uses Id2 to overcome antiproliferative function of RB protein  ADDIN EN.CITE (Lasorella et al. 2000).  p53 is another important TS gene that is mutated in more than 90% of SCLC cases (Yokota et al. 2004).  Inactivation of this gene has been related to up-regulation of Id2  ADDIN EN.CITE (Wilson et al. 2001).  Therefore it appears that genetic events involved in pathogenesis of SCLC might in parts execute their effects by upregulation of Id2.  However there are other regulatory mechanisms within normal cells to control Id2.  Some of these mechanisms involve shuttling Id2 from the nuclei into the cytoplasm where it is functionally inactive and also expose to degrading mechanisms  ADDIN EN.CITE (Kurooka et al. 2005).  Considering all these findings collectively, one can speculate that Id2 upregulation might be a result of early events such as RB and p53 mutation when it helps hyper-proliferation of tumour cells.  However, cell defensive mechanisms might actively transport it into the cytoplasm; thus it may be possible that the diminishment of the nuclear Id2 and hence its function, rather than the increment of cytoplasmic Id2, has contributed to the longer patient survival.  Similar prognostic effect has been reported for Id2 in breast cancer, where high cytoplasmic expression of the protein was correlated with favourable prognosis for the patients.  Interestingly when Id2 was forced to over-express in a breast cancer cell line, its main localisation shifted into the cytoplasm and reduced invasiveness of the cell line.  Therefore it appears that translocation of excess Id2 from nucleus into cytoplasm contributes in reducing tumour progression, at least for a short period in SCLC.  

3.2.	Summary, conclusion and next question 
  
Id1, Id2 and Id3 are over-expressed in SCLC tissues and cell lines and Id4 is over expressed in SCLC tissues. Association of the increased expression of these proteins with malignant characteristics of the cells indicated possible important roles played by these proteins in the malignant progression. Although the increased Id1, Id3 and Id4 in SCLC cells is not significantly correlated patient’s outcomes, the increased expression of Id2 in cytoplasm of SCLC may be a highly relevant prognostic factor to predict patient survival.  
These results provided reasonable foundation to govern taking further steps to investigate possible role of Id proteins in pathogenesis of SCLC.  Therefore attempts were made to design further experiments to answer new questions raised.  The first question asked was:
What are the consequences of reduction of Id proteins expression in SCLC malignant cell lines that express them with high levels?  
Considering the limited time given to a PhD program, it was not practically possible to look into all four proteins.  Therefore Id3 protein was chosen to be investigated in the next part of the study, for two following reasons:
1.	Id3 showed the strongest expression in both cell lines and tissue sections of SCLC.  Particularly in tissue sections, the nuclear localization of this protein was predominant and highly positive, which is likely to be the cellular compartment Id3 is active in.  





Reducing Id3 experession will reduce tumourigenisity in malignant SCLC cell line in vitro and in vivo.

To test this hypothesis, experiments were designed and performed with following aims:
1.	To reduce the expression of Id3 in the cell line with highest levels of the protein (GLC-19) using si-RNA technique.
2.	To establish transfectant cell lines stably expressing low levels of Id3 protein.
3.	To compare malignant behaviour of these low Id3 expressing cell lines with control cell line in vitro tumerigenisity related assay experiments.
4.	To test the tumerigenic ability of the transfectant cell lines in live animals (in vivo) and compare the rate and the size of tumour formation.  












































It was shown that Id family proteins (Id1, Id2, Id3 and Id4) are generally overexpressed in SCLC malignant cell lines comparing to a normal bronchial cell line Beas-2b.  The expressions of the four proteins were examined in 26 pairs of SCLC malignant tissue sections and their adjacent normal bronchial epithelial sections from the same patient.  This investigation also presented upregulation of four Id proteins in malignant cells in comparison to their normal epithelial counterparts. Survival analysis using close to 100 biopsy samples diagnosed as SCLC suggested a correlation between higher levels of Id2 and longer patients’ survival. Therefore it was proposed that Id proteins might have a significant role in tumourigenisity of SCLC.  
To start investigating the nature of the role speculated for Id family proteins in SCLC, focusing on one protein at a time, Id3 was chosen as the first candidate gene to study.   In the first part of this study Id3 presented the strongest expression among the four proteins.  There were strong evidence indicating possible roles for this protein in the pathogenesis of other cancers such as hepatocellular carcinoma, prostate cancer and colorectal adenocarcinoma.  In head and neck squamous cell carcinoma, forced expression of Id3 reduced invasiveness of tumour cells via interfering with transcription of matrix metalloproteinase 2 (MMP2)  ADDIN EN.CITE (Higashikawa et al. 2009).  Inversely in pancreatic carcinoma where Id1, Id2 and Id3 were over-expressed, Id1/ Id3 double knockdown reduced metastasis potential of malignant cell lines. However the potential role for Id3 was not investigated in SCLC so far. 








RNA silencing, as a mechanism came to attention first in 1980s during work on plant genetic modification when it was noticed that extra copies of a gene caused decrease in its expression instead of the predicted increase (van der Krol et al. 1990).  However it wasn’t before 1998 that after extensive experiments in flies and worms the term “RNA interference” was introduced to scientific world for the first time (Fire et al. 1998).  It was suggested that it was an ancient mechanism that protected the host cell and its genome against viral infections that used double-stranded RNA (dsRNA) during at least one stage of their life cycle.  This system uses protein machinery that degrades dsRNA by an enzyme called dicer into small segments around 20 nucleotide pair (Hannon 2002).  Realising new windows this mechanism could open on gene function research, many efforts were made to use the mechanism to silence genes in mammalian cells.  These attempts weren’t successful until short, double stranded RNA molecules of less than 30 nucleotide pairs long were used which unlike the long molecules were unable to induce the interferon response, therefore could silence gene expression in a sequence specific manner  ADDIN EN.CITE (Elbashir et al. 2001).  
The principal of siRNA technique is that when a dsRNA is introduced to a cell, it is cleaved by a cytoplasmic ribonuclease III enzyme called dicer and get assembled into RNA induced silencing complex (RISC) (Filipowicz 2005), which degrades one of RNA strands, the sense or passenger strand, keeping the antisense or guide strand (Leuschner et al. 2006).  This strand then targets the complementary sequence of the cell mRNA binding RISC to it which degrades it by its nuclease activity  ADDIN EN.CITE (Sontheimer 2005; Kutter et al. 2008).  Figure 3.1.









In mammalian cells RNA interfering (RNAi) can be triggered by DNA based plasmid or viral expression vectors designed to express short hairpin RNA molecules (Silva et al. 2004) or by synthetic short interfering RNA (siRNA) molecules (Sachse et al. 2004). In the latter the siRNA don’t need to be cleaved by dicer and directly integrates into RISC and degrades the target mRNA, resulting in gene silencing.  However this effect is only temporary and is suitable for experiments that need 3 to 7 days of gene knock down.  For longer or stable gene silencing the vector method is more suitable (Silva et al. 2004).   
In this study, a RNA sequence containing hairpin sequence was designed to target Id3 mRNA and inserted into a plasmid vector, which after being delivered into GLC-19 cells, created transfeced cell lines which stably expressed lower levels of Id3 comparing to the parental cells and the empty vector transfected control cell line. 

4.2.1.2.	p SilencerTM 4.1- CMV neo map












Figur 4.2:  p SilencerTM 4.1- CMV neo map, containing ampicillin and neomycin resistance sequences and siRNA insertion site with BamH1 and HindIII restriction sites.  This picture is taken from Ambion p SilencerTM 4.1- CMV neo kit instruction manual.
4.2.1.3.	Design of oligonucleotide targeting Id3 mRNA 

Complete Id3 mRNA sequence was searched in NCBI nucleotide data base and the complete coding sequence was determined.  Using Ambion siRNA target finders in Design tool, the offered target sequences were considered for a) their GC contents, b) their homology to Id3 and no other human DNA or RNA sequence and c) the position of target sequence in Id3 protein coding sequence.  According to these criteria, target sequences number 16, 18, 20 and 21 were chosen for further investigation.  These targets had < 70% GC content, 100% homology to Id3 and positioned in four different positions on coding region of Id3 (55,142,212 and 319).  The vector used in the experiment, p SilencerTM 4.1- CMV neo, was specified in the design tool and using chosen target sequences, sense and antisense oligonucleotides with 55 base pairs were designed, saved and ordered from manufacturer (invitrogen).

















Figure 4.3:   Id3 Target 18 sequence (A), siRNA silencing constructs (B), and annealed siRNA template insert into plasmid vector (C).






BamH1     sense sequence             Loop           antisense sequence     

ii)   Antisence strand
5'-AGCTTAACCACTGCTACTCCCGCCTGTCTCTTGAACAGGCGGGAGTAGCAGTGGG-3'
HindIII     antisense sequence              Loop           sense sequence

C)	Annealed siRNA template insert
BamH1     sense sequence             Loop           antisense sequence           HindIII
5'-GATCCCCACTGCTACTCCCGCCTGTTCAAGAGACAGGCGGGAGTAGCAGTGGTTA-3'     
3’-GGGTGACGATGAGGGCGGACAAGTTCTCTGTCCGCCCTCATCGTCACCAATTCGA-5’
4.2.1.4.	
4.2.1.5.	Making competent DH5α 
From DH5α E.Coli bacteria cell solution, 100 µl of was removed from glycerol stock stored at - 80oC and cultured in 10 ml of Liquid Broth (LB) medium at 37oC and 225 rpm for 16 hours.  The following morning, one ml of the cloudy bacterial culture was transferred into 100 ml of super optimal medium (SOB) medium in another conical flask, containing 2mM magnesium salt solution.  This was incubated at 37oC and 225 rpm for about 90 minutes or until the optical absorbance value at OD 550 reached 0.4 nm. The culture was dispensed into 8 x 12.5 ml portions in universal tubes and cooled on ice for 10 minutes.  Then the tubes were centrifuged in pre-chilled centrifuge at 4oC for 10 minutes at 2500 rpm, and then placed on ice. After discarding the supernatant, the pellets were resuspended in a total of 66 ml of RF1 calcium chloride/glycerol buffer (PH 5.8) and incubated on ice for 10 minutes. The tubes were centrifuged once again with the same conditions as before. This time after discarding the supernatant, pellets were resuspended in a total of 16 ml of RF2 calcium chloride/glycerol buffer (PH 6.8).  The samples were pooled together and dispense into one ml aliquots into cryotubes and then flash frozen in liquid nitrogen before being transferred immediately to the - 80oC freezer.  
4.2.1.5.	Cloning the hairpin siRNA oligonucleotide into pSilencer 4.1-CMV neo
4.2.1.5.1.	Anealing the hairpin siRNA template oligonucleotides 
From each oligonucleotide construct received from manufacturer (Invitrogen) 1µg/µl working dilutions in TE buffer were prepared.  Then the annealing mixture was assembled as follows:
	2 µl   sense oligonucleotide
	2 µl   antisense oligonucleotide
	46 µl 1X DNA annealing solution
This mixture was heated to 90oC for 3 minutes, then cooled to 37oC and incubated at 37oC for 1 hour.  The annealed hairpin siRNA was placed on ice to be ligated into the vector.
4.2.1.5.2.	Ligating annealed siRNA template insert into pSilencer 4.1 CMV neo
Final concentration of 8 ng/ µl was made by diluting 5 µl of annealed hairpin siRNA template insert with 45 µl of nuclease free water.  Then two ligation reactions were set up as follows:
Component					Plus-insert	Minus-insert                 
Diluted annealed siRNA insert		1 µl		-----
1 X DNA annealing solution		------		1 µl
Nuclease free water				6 µl		6 µl
10 X T4 DNA ligase buffer			1 µl		1 µl
pSilencer 4.1- CMV neo vector 		1 µl		1 µl
T4 DNA ligase (5 U/µl)			1 µl		1 µl
The minus-insert reaction with was considered as negative control.  The ligation reactions were incubated at 16oC overnight. The following day, this plasmid would contain oligonucleotide hairpin insert and used for transformation of competent bacteria.
4.2.1.6.	Transformation of competent E-coli bacteria with vector containing hairpin insert
Competent E-coli cells were thawed out on ice. For each ligated plasmid containing a oligonucleotide hairpin insert, one sterile falcon tube was prepared containing 200 µl of bacteria cells. In this study four tubes were prepared for four ligated plasmid reactions. One tube was also prepared for minus insert plasmid. To each corresponding tube10 µl of plasmid DNA solution containing 10 ng plasmid DNA was added.  The tubes were mixed gently by swirling and incubated on ice for 30 minutes, then incubated at 42oC for 90 seconds exactly. Tubes were then transferred on ice immediately where they were incubated for 2 minutes.  From SOC medium (SOB medium containing 20 mM glucose) that was preheated to 42oC, 800 µl was added to each tube and incubated at 37oC for 1 hour, agitating at 225 rpm.  As a negative control, one reaction was prepared without plasmid DNA.  
The reactions were cultured on LB agar plates containing 100 µg/µl ampicillin as selective antibiotic.  For each reaction, including minus insert reaction, 3 different plates with densities of 50, 100 and 200 µl transformed bacteria per plate were cultured.  Also for each reaction one plate with 100 µl transformed bacteria was cultured on no-antibiotic agar.  This was to control the antibiotic quality and activity.  The other controls were two plates cultured with 100 µl of untransformed bacteria, one with and the other without antibiotic.  These controls were set up to ensure the quality of bacteria cells and also their antibiotic sensitivity.  It was expected to see bacteria lawn grown on plates without antibiotics, and no growth of untransformed bacteria on the antibiotic plate.  The transformed bacteria were expected to make colonies according to the density of bacteria cultured on antibiotic plates.  The minus-insert bacteria was expected to make some colonies, but less than the plus insert bacteria on antibiotic plates.  Plates were incubated at 37oC overnight.  
The following morning, one colony of each transformed bacterium containing a different oligonucleotide insert and also from minus-insert bacteria was isolated and re-cultured in 10 ml of LB medium containing 100 µg/µl ampicillin at 37oC and 225 rpm for 16 hours overnight.
Using spectrophotometer, bacterial growth was assessed after overnight culture.  The growth was considered to be in the log phase and therefore optimal for plasmid extraction when it attained an OD550 of 1-1.3.  At this point bacterial culture was used for plasmid extraction.

4.2.1.7.	Extraction of plasmid DNA from transformed bacteria
Plasmid DNA containing siRNA oligonucleotide insert was purified using QIAGEN plasmid purification kit, following Midi-prep instruction.  In this study there were four bacteria sample corresponding to four target siRNA inserts and one minus insert sample.  The minus insert plasmid DNA was used in transfection reaction to produce empty vector transfected cell line which would be used as control group alongside si-Id3 cell lines.  
The bacteria cells were harvested by centrifuging for 15 minutes at 4oC at 6000 xg. After discarding the supernatant, the pellets were resuspended completely in 4ml Buffer P1.  The bacteria cells were lysed by adding 4 mls of lysis buffer P2 and inverting the tubes 6 times.  The tubes were incubated at room temperature for 5 minutes.  Then 4 mls of pre-chilled neutralizing buffer P3 was added to each tube immediately and the content was mixed thoroughly by inverting 6 times.  The tubes were incubated for 15 minutes on ice before being centrifuged at 20000 x g for 30 minutes at 4oC and removing supernatant.  The supernatant containing plasmid DNA was removed promptly and transferred into fresh tubes for second round of centrifugation at 20000 x g for 15 minutes at 4oC.  The supernatant was removed and added to pre-equilibrated Qiagen 100 tips (with 4 ml of buffer QBT) and allowed to flow through the resin by gravity. The flow through was discarded.  Then the Qiagen 100 tips were washed twice with 10 ml of buffer QC and the flow through was discarded. The plasmid DNA was eluted from the resin with 5 ml of buffer QF to each Qiagen tip.  DNA precipitation was achieved by addition of 3.5 ml of room temperature isopropanol to the elute, mixed and spun at 20000 x g for 2 hours at 4oC.  Each pellet was resuspended in 1.5 ml of 70% ethanol, transferred into a 1.5 ml microtube  and spun again at 20000 x g for 30 minutes at 4oC. After removing the alcohol, the pellets were air-dried for 10 minutes at room temperature followed by mixing and dissolving the DNA pallet in 20 µl of TE buffer PH 8.0.  The concentration of plasmid DNA was determined by NanoDrop spectrophotometer in nucleotide mode.

4.2.1.8.	Verification of insertion of hairpin siRNA 

4.2.1.8.1.	Sequence analysis of plasmid DNA 
To confirm the insertion of siRNA oligonucleotide inside plasmid DNA, an internal generic sequence primer set (sense and antisense) recommended by Ambion for pSilencer 4.1-CMV expression vector was synthesised by invitrogen and used for sequencing plasmid DNA purified from transformed bacteria. 
Forward sequence:
5’ – AGGCGATTAAGTTGGGTA – 3’
Reverse sequence:
5’ – CGGTAGGCGTGTACGGTG – 3’ 
The samples were prepared by diluting the plasmid DNA into 100ng/µl concentration and the primers into 0.6 µg/µl concentration.  The sequencing was performed by Cogenics Technologies. 
The sequencing showed the presence of each siRNA hairpin within corresponding pSilencer 4.1-CMV vector.  Figure 4.4 is an example showing presence of target 18 oligonucleotide.  This example was chosen since this is the plasmid DNA that was used eventually in stable transfection reaction in this study. 

Figure 4.4: Sequencing proved insertion of siRNA oligonucleotide targeting sequence 18 into pSilencer 4.1-CMV neo.
 
    5'-AGCTTAACCACTGCTACTCCCGCCTGTCTCTTGAACAGGCGGGAGTAGCAGTGGG-3'

4.2.1.8.2.	Double digestion of plasmid DNA 
Another confirmation for the presence of the insert inside plasmid DNA was attained by double digestion of plasmid DNA with BamH1 and HindIII restriction enzymes on both side of the insertion and run the product on agaros gel.  Expectation was that double digestion resulted in a 55 bp band which would be interpreted as the siRNA insert, proving the insertion was in the right place.
Four double digestion reactions were set up, each corresponding to one siRNA target as follows.  In these reactions buffer 2 and BSA were choice of enzyme buffers since they provided 100% efficiency for both enzymes.





	14 µl  		Plasmid DNA (equivalent to 1.5 – 2 µg DNA)
The reaction was mixed thoroughly and incubated at 37oC for 1 hour following incubation at 68oC for 10 minutes to inactivate the enzymes.

4.2.1.8.3.	Single and double digestion of empty vector plasmid DNA
To verify the circularity of the DNA extracted from the minus-insert transformed bacteria, the DNA was subjected to one round of double digestion and two rounds of single digestions using restriction enzymes mapped on pSilencer 4.1-CMV neo.  Double digestion was performed the same enzymes, buffers and method explained in previous section.  Single restriction digestion reactions used BamH1 and HidIII enzymes separately with the following reaction composition:
	2 µl 		Buffer 2
	2 µl		BSA(10X)	
	0.6 µl		BamH1 or HindIII		
	300ng  	Plasmid DNA 
To each reaction distilled water was added to make up to 20 µl.  The reactions were incubated at 37oC for 1 hour and inactivated at 68oC for 10 minutes.

4.2.1.8.4.	Agarose gel electrophoresis
A 1% agarose electrophoresis gel was prepared in 0.5 X TBE buffer and 1/5000 dilution of ethidium bromide. From each double digested DNA sample, 20 µl was run alongside equivalent to 1 µg of undigested DNA.  To each digested and undigested sample 4 µl of sample loading buffer was added. Samples were loaded on the gel at 80 V for 1 hour using 0.5 TBE buffer, alongside DNA marker VIII. The bands were visualized using a UV transilluminator .  The faint bands with small molecular weights were considered as the 55 bp oligonuclotide inserts within plasmid DNA (figure 4.5). 





















Figure 4.6:  DNA gel electrophoresis of double and single restriction digestion of empty vector plasmid DNA.  Columns 1, 2: markers, column 4: undigested DNA, column 5 double digested DNA, Column 6 and 7: HindIII and BamH1 single restriction enzyme digested DNA respectively.  All digestion reactions have produced single bands at approximate molecular weight of pSilencer 4.1-CMV neo, indicating the circularity of the original DNA and its intact restriction sites.  No small bands indicating a short inserted sequence is visible.


4.2.1.9.	Transient transfection of GLC-19 with Id3 siRNA inserted vector.
In this study the transfection reagent used was Lipofectamine TM 2000 (Invitrogen) and the manufacturer recommended protocol for suspension cells was followed. 
First the duration of transfection was optimised. Three 6 well culture dishes were labelled for 24, 48 and 72 hours transfection duration respectively. In each dish, wells were labelled for targets 16, 18, 20 and 21. Parental cells in normal growth medium were used as positive control and one well in each dish were set up without any plasmid DNA as negative control. Using normal growth medium without antibiotics, two ml of cell suspension containing 20 X 105 GLC-19 cells were cultured in each well of 6 well dishes.  OPTi-MEM I Reduced Serum Medium was used as the diluents for both DNA and transfection reagent (TR).  Diluents solutions containing 4 µg DNA per 250 µl medium per well and 10 µl Lipofectamine 2000 per 250 µl medium per well were prepared separately and incubated at RT for 5 minutes.  After this time, DNA and Lipofectamine 2000 were combined gently by twirling and incubated for 20 minutes at RT. At the same time, 250 µl OPTi-MEM I without DNA was added to 250 µl Lipofectamine 2000 per negative control well.  The DNA- TR mixture was added to each well at 500 µl per well except for negative control well to which Lipofectamine 2000 without DNA was added. The transfection reaction was mixed with cells by twirling the dishes gently.  Dishes were incubated at 37oC, 5% CO2 and 90% humidity.

4.2.1.10.	Assessment of transfection efficiency
In order to determine which siRNA target, and what duration of experiment provided the best knock down of Id3 mRNA, the gene’s mRNA expression was assessed by Quantitative Polymerase Chain Reaction (Q-PCR), using complementary DNA (cDNA) as starting material and the house-keeping gene, β-actin as the normalizer.   

4.2.1.10.1.	Total RNA extraction 

Total RNA content of cells were extracted using RNeasy Mini extraction kit (Qiagen).
Transfection dishes were taken out of incubator after 24, 48 and 72 hours respectively, cells were pippetted out of each well and transferred into 1.5 ml microtubes.  Cell pellets were obtained by centrifugation and cells were disrupted by adding 600 µl of buffer RLT provided in the kit, containing 1% 2β-ME.  The samples were homogenised using QIA Shredder spin column.  To precipitate RNA, the flow-through containing homogenised lysate was mixed with equal volumes of 70% ethanol in nuclease free water and mixed by pippetting. The mixture was transferred to RNeasy spin column and centrifuged briefly at 130000 rpm and the flow through was discarded. 
At this stage, to ensure there is no DNA contamination, on-column DNase digestion was performed. From wash buffer RW1, 350 µl was added to the spin column and centrifuged briefly.  After discarding the flow through, 10 µl of DNase stock solution was mixed with 70 µl of buffer and added to each spin column membrane directly and incubated at room temperature for 15 minutes.  Then the spin columns were washed again with buffer RW1.  The flow through was discarded after centrifugation.  To wash the ethanol out, two rounds of 500 µl of buffer RPE was added to the column and centrifuged.  After transferring the spin columns onto new nuclease free microtube, RNA was eluted by adding 30 µl nuclease free water to the column and centrifugation at 13000 rpm for 1 minutes.  
The RNA concentration was measured by NanoDrop in nucleotide mode at 260nm basic wavelength, choosing RNA-40 option as constant factor.  Purity of extracted RNA was analysed by RNA 6000 Nano Assay using RNA Nano LabChip (Agilent Technologies).  All samples were assessed to highly pure (RNA integrity numbers of > 9.2) and suitable for use as cDNA synthesis template.  
Samples were stored at - 80oC.  The extraction protocol was repeated for 48 and 72 hours transfection reactions on corresponding days after the start of the transient transfection experiment. 

4.2.1.10.2.	Synthesis of first strand cDNA 
First strand cDNA was synthesised using SuperScriptTM III First-Strand System for Q- PCR (invitrogen) kit and instruction manual.  In this experiment total RNA was used as starting material and cDNA synthesis was primed with 50 µM oligo-dT.  All heating steps were performed in a PCR heating plate.  The primer annealing mixture was prepared as following:

	Total RNA		Equivalent to 0.5 µg
	50 µM oligo-dT	 	1 µl 
	10 mM dNTP mix		1 µl	
	DEPC water 			to 10 µl
This mixture was incubated at 65oC for 5 minutes and then placed on ice for at least 1 minute. Then cDNA synthesis Master-mix was prepared (per reaction) as follows:
	10X RT buffer		2 µl
	25 m MgCl2			4 µl
	0.1M  DTT			2 µl
	RNaseOUT 			1 µl
	SuperScript III RT		1 µl
10 µl of Master-mix was added to each RNA/primer mixture, and was incubated at 50oC for 50 minutes. The reaction was terminated at 85oC for 5 minutes and then chilled on ice. To each reaction one µl of RNase H was added to degrade RNA template.
One negative control sample was prepared with the same ingredients except for reverse transcriptase enzyme which was replaced by water, labelled as No-RT cDNA, and heated the same as others.
Synthesised cDNA was stored at - 20oC.    

4.2.1.10.3.	Q-PCR 
One set of forward and reverse primers were designed to amplify Id3 gene expression using GeneScript website primer design tool.  At least one of the primers expanded exon-exon junction in the coding region of Id3 DNA sequence, to avoid any DNA amplification.
The following primer sequences were used for Id3 gene amplification:
P1:   5’- CGCGTCATCGACTACATTCT -3’
P2:  5’- GAGCTCGGCTGTCTGGAT -3’
The uniqueness of the 99 base pair amplicon amplified by this set of primers was confirmed by Blast searching to ensure that it exhibited no specificity towards any other human sequence.

4.2.1.10.4.	Optimizing annealing temperature 
Although there was an annealing temperature recommended by the manufacturer (Invitrogen), in order to make sure of an optimal PCR reaction, a gradient temperature PCR reaction was performed for both Id3 primer set.  
13 PCR samples were prepared for each primer set with following composition:
	Syber Green  		5 µl
	Primer 1			1 µl
	Primer 2			1 µl
	Nuclease free water		2 µl
	cDNA				1 µl
The cDNA used for the first 12 samples was GLC-19 cDNA. The 13th sample contained No-RT cDNA as a negative control.




PCR reaction ended with final extension at 72oC for 10 minutes.
The PCR products were run on 1% agarose gel containing 1/5000 ethidium bromide for 1 hour at 80V (Figure 4.7).
There was one single band across different annealing temperature.  Therefore, for convenience, since the optimal temperature obtained for β-actin primer set was 63oC, the same was chosen for annealing Id3 primers. 

Figure 4.7:  DNA gel electrophoresis of gradient temperature PCR products to optimize annealing temperature for Id3 primers.  The PCR reaction showed single DNA product amplification across different annealing temperatures indicating suitability of all temperatures within the range for Id3 gene amplification. 
4.2.1.10.5.	Q – PCR reaction
Using cDNA synthesised with RNA extracted from transient transfection cells, PCR samples were prepared with the same composition as section 4.2.2.9.4.
For each cDNA two sets of triplicates were prepared, one using Id3 and the other β-actin primer sets. 




	Data acquisition	 61oC			15 seconds
	Read plate
After completion of 40th cycle:
	Final extension 	72oC			30 seconds
	Melting curve 	65-95oC		1oC increment for 10 minutes
This experiment contained two sets of negative control triplet samples.  One set used No-RT cDNA and the other contained only water.
At the end of the experiment, melting curves were observed for presence of primer dimers and since there were no extra curves indicating this, the relative expression of Id3 was calculated.
4.2.1.10.6.	Calculation of relative quantity of Id3
The average of C(t) values for each triplicate was calculated, both in Id3 samples and β-actin (BA)samples. This was called C(t).  
For each sample corresponding to a target siRNA transfection, the ΔC(t) for each sample pair was calculated as:   ΔC(t) = BA C(t) – Id3 C(t)
Taking parental GLC-19 cell line as the calibrator ΔΔC(t) was caculated with the formula:  ΔΔC(t) = Sample  ΔC(t) – GLC-19 ΔC(t)
Finally relative fold difference of Id3 expression in each sample to GLC-19 was calculated using the formula:  Realtive fold difference = 2 – ΔΔC(t)

4.2.1.11.	Stable Transfection
4.2.1.11.1.	Pre-requirement experiments for selection process

Since GLC-19 cells grew in suspension, it was predicted that after transfection, the conventional ring cloning procedure would not be practical for single colony selection.  The method used instead, was semisolid growth medium selection method, using ClonaCell-TSC (StemCell Technologies).  In this method the colonies would grow in semisolid medium in fix positions, therefore are separable by pipetting.  
ClonaCell-TSC is a methylcellulose based semisolid media that allows simultaneous selection and cloning of transfected cells in one step.  After addition of appropriate selective antibiotic, resistant transfected cells from one progeny stay together as they divide, making suspended colonies of discrete clonal cells.  After two weeks these colonies became visible and harvested into separate growth spaces.  
Two sets of optimizations are necessary before using this growth medium:
1.	Determination of growth and plating efficiency in ClonaCell-TSC media.
2.	Determination of lethal antibiotic concentration in ClonaCell-TSC media.

4.2.1.11.1.1.	Determination of growth and plating efficiency of GLC-19 cells in ClonaCell-TSC media
As GLC-19 was not listed among cell lines tried and reported by the manufacturer, this experiment was performed in order to verify suitability of the system for GLC-19 cells.
Using trypan-blue and haemocytometer, different concentrations of cells were prepared.  Volumes of ClonaCell-TSC medium without antibiotics was mixed with cell suspensions at 4/1 v/v ratio to make serial cell concentrations in semi-solid medium. One ml of each cell concentration was transferred to 35 mm petri dishes in duplicates.  The dishes were incubated at 3 7oC, 5% Co2 and > 95% humidity for 2 weeks.
After two weeks the colonies visible by naked eyes were counted, and plating efficiency was calculated using this formula: 
Plating efficiency = number of colonies X 100 /number of cells plated
The results are summarised in table 4.1.

	Cells plated	Colony count	Efficiency (%)
Dish 1 – 2	150	92 – 93	61 – 62
Dish 3 – 4	100	70 – 92	70 – 92
Dish 5 – 6	50	35–33	70 – 66











According to the manufacturer recommendation, efficiencies less than 25% indicated unsuitability of semisolid media for transfected cells.  Since in all cell concentrations the calculated efficiency was 61 – 92% the system was decided to be suitable for GLC-19 cells.

4.2.1.11.1.2.	Determination of lethal antibiotic concentration in ClonaCell-TSC
In order to select antibiotic resistant colonies from pool of transfected cells, G-418 that is a homolog of neomycin was used.  The optimal antibiotic concentration that killed parental cells efficiently was determined. Using Trypan Blue, a suspention of 1000 viable GLC-19 cells/ml were prepared in growth media.  From ClonaCell-TSC stock, 2.4 ml was transferred to each six of 15 ml tubes.  To five tubes 0.3 ml of increasing concentrations of G418 was added and to the sixth tube 0.3 ml growth media was added.  Next, 0.3 ml of cell suspension containing 100 cells was added.  Tubes were mixed thoroughly and let to sit for 5 minutes to settle down.  One ml of cell suspension /antibiotic/ ClonaCell-TSC mixture was transferred into 35 ml petri dishes.  The sixth dish contained no antibiotics.  The dishes were incubated at 3 7oC, 5% Co2 and > 95% humidity for 2 weeks.  After two weeks of incubation, the colonies visible to naked eye were counted in each dish. The results are summarised in table 4.2.  The lowest antibiotic concentration killing all the cells, 1 mg/ml, was considered as the optimal antibiotic concentration for selection of transfected cells.

Table 4.2:  Number of colonies grew at serial concentrations of G418 in ClonaCell-TSC medium after two weeks.








4.2.1.11.2.	Stable transfection of GLC-19 cells 
Using target 18 siRNA plasmid DNA a transfection reaction was set up in a 6 well plate according to the protocol explained in section 4.2.2.8 with the same composition of transfection reagents and cell density.  One well was set up as negative control, using empty vector plasmid DNA in transfection reaction.  One well was cultured with only GLC-19 cells without any transfection reagents.  Selection process was started after 24 hours.   
4.2.1.11.3.	Selection of single si-Id3 colonies
From transfected pool in each well cell suspensions containing 1000 cells/ml were prepared in normal growth media without antibiotic.  Eight ml of ClonaCell-TSC medium was mixed with one ml of 10 mg/ml solution of G418 in normal medium and One ml of cell suspension in a universal tube. Therefore this mixture contained 100 cells and final concentration of 1 mg/ml G418.  This mixture was left to settle for 15 minutes and then transferred into a 10 ml petri dish.  A separate dish was prepared with the same composition but using empty vector cell line.  The dishes were incubated at 3 7oC, 5% Co2 and > 95% humidity for two weeks.

4.2.1.11.4.	Harvest of single transfected colonies 
The wells were inspected for macroscopic colonies.  Several colonies were taken out of semisolid media one by one using a pasture pipett, each transferred into one well of a 96 well plate containing 1 ml of normal growth media with 1 mg/ml G418.  The wells were inspected carefully under microscope to ensure it contained only one single colony.  Then the colonies were disaggregated by pippeting.  The 96 well dish was incubated in 37oC incubator and observed every day for cell growth.  When the cell population seemed to have grown enough, cells were subcultured.  This process continued until cell population was enough for RNA extraction. 

4.2.1.12.	Relative expression of Id3 mRNA in si-Id3 single colony cells
RNA extraction was performed using Qiagen RNeasy Mini prep kit. Section 4.2.2.9.1.  The concentration of extracted RNA was measured by NanoDrop and the purity was bioanalysed by RNA 6000 Nano assay.  Out of 12 RNA samples, 10 showed reasonable concentration and high Integrity numbers indicating good purity of extracted RNA.  These 10 cell lines were labelled as G-Id3-1 to 10.  The RNA extracted from these 10 cell lines were used for cDNA synthesis by SuperScriptTM III First-Strand System (Invitrogen) as explained in section 4.2.2.9.2.  The cDNA samples were used in a Q-PCR reaction (section 4.2.2.9.3).  
Two sets of Id3 and β-actin primers (see section 4.2.2.9.5) were used to amplify the two genes in triplicate PCR reactions from 10 si-RNA transfected cDNA samples.  The relative expression of Id3 was calculated using following 2 – ΔΔC(t) formula that was explained in section 4.2.2.9.6.

4.2.1.13.	Id3 protein expression in si-Id3 transfected cell lines
Using western blot technique, Id3 protein expression in two selected transfected cell lines were compared to parental (GLC-19) and empty vector control cell line using technique, reagents and antibodies explained in section 2.2.4.

4.2.2.	Id1 and Id2 protein expression in si-Id3 cell lines













To determine the difference in growth rate of si-Id3 cell lines versus empty vector control cell line, proliferation assay was performed. The reagent used was CellTiter 96 AQueous One Solution Reagent which contains a tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; MTS] and an electron coupling reagent (phenazine ethosulfate; PES).  PES combines with MTS and form a stable solution.  This allows the experiment to be performed in one step.  
Live cells reduce the MTS compound into a coloured formazan product which is soluble in culture medium.  This colour change is measurable at 490nm using spectrophotometer. 

4.2.3.1.2.	Setting up standard curve reactions
In each cell line, cells were counted using Trypan Blue and haemocytometer, and disaggregated into single cells with pipetting.  In a 24 well petri dish, serial cell densities were prepared in normal growth media.  This made 11 samples ranging from 200000 cells to 500 cells per well.  The 12th well contained “blank” sample, containing media only. One dish was set up for each cell line.
The first column of a 96 well petri dish was filled with 100 µl of blank sample.  100 µl the rest of cell dilution samples were transferred into other wells in triplicates in a systematic order. To each well, including blanks, 20 µl of MTS solution was added and mixed gently by twirling the dish.  The dish was incubated at 37oC, 5% Co2 and 95% humidity for exactly 4 hours.  After this period, colour development was assessed at 490 nm wavelength using spectrophotometer.




Figure 4.8:  Standard curve for GLC-19 cell line.  The curve equation and regression value of the curve is demonstrated. 

4.2.3.1.3.	Proliferation Assay
This assay was set up for eight days, with four readings on day 2, 4, 6 and 8. For each cell line, four 6 well dishes were set up, 3 wells of each assigned to produce triplicate samples.  On day one, each well was cultured with one ml growth media containing 5000 cells.  
On day 2, 4, 6 and 8, 100 µl of triplicates of each cell line were transferred to wells of a 96 well dish. The first column was filled with 100 µl of growth media.  These cells were disaggregated by gentle pipetting.  Then to each well 20 µl of MTS solution was added, mixed and incubated at 37oC, 5% Co2 and 95% humidity for exactly 4 hours. After this period the colour absorbance of samples was determined by spectrophotometer at 490 nm wavelength.  Using standard curve equation for each cell line, the cell count was calculated in each well and the average of triple samples of each cell line was calculated.  
The final average cell count for each transfected cell line was compared to the control cell line using Student t-test to evaluate statistical significance of the difference.
4.2.3.2.	Soft Agar Assay
To evaluate the ability of si-Id3 transfected cell lines to produce colonies in an anchorage independent environment soft agar assay was performed. The ability of tumour cells to produce colonies in a substrata free environment like soft agar is considered one of the best indications of tumourigenisity of a group of cells: the more malignant a tumour cell, the greater its ability to form clusters of cells  ADDIN EN.CITE (Freedman et al. 1974; Zwiebel et al. 1982; Liu et al. 2001).    

For this experiment, three wells of a 24 well petri dish were labelled to produce triplicates for each cell line.  Then 50 ml of 1.4% and 50 ml of 1% low melting temperature agarose (LMA) were made in PBS buffer by heating the mixture in microwave oven till the agarose is melted.  These solutions were autoclaved and then cooled down to 42oC in a waterbath.  A double concentrated growth media was prepared containing 20% FCS, 2mg/ml G418 and 4mM/L L-glutamin. 
To make the underlayer same volumes of 1.4% LMA and the double concentrated growth media were mixed. This gave the final LMA concentration of 0.7%. From this mixture, 0.5 ml of was transferred into each labelled well and let to set in the refrigerator for 1/2 hour.
For the cell layer, from each si-Id3 cell line and the control cell line, cell suspensions containing 20000 cells/ml were prepared.  Same volumes of 1% and each cell line suspension were mixed.  This gave the final concentrations of 0.5% LMA and 10000 cells/ml. From this mixture, 0.5 ml containing 5000 cells was transferred to the underlayer in each corresponding well. The cell layer was set in the refrigerator for 10 minutes and then transferred into 37oC incubator with 5% Co2 and 95% humidity level.
The growing cells were fed by 0.3 ml of 0.5% LMA/growth media twice a week. 




4.2.4.1.	Inoculation of nude mice by tumour cells 
Three groups of 8 male immune-incompetent CD-1, 6 weeks old nude mice were used in this study.  Mice were weighed before injection in order to have reference in case of weight loss after injection.
In each cell line, cells were disaggregated by pipetting and counted using Trypan Blue and haemocytometer and cell suspensions containing 5 x 107 cells/ml were prepared in PBS.  Same volumes of cell suspension and matrigel were mixed for each cell line.  To each animal 200 µl of cell/matrigel mixture containing 5 X 106 cells was injected.  Injections took place subcutaneously in shoulder area.
Inoculated mice were weighed three times a week, and the sites of injection were observed for signs of tumour growth.  When tumours started to appear, three dimensions (length, width and depth) of tumours were measured using a calliper.  On the day 20 of injection, animals were sacrificed using Co2 chamber.  From each animal primary tumour, liver, auxiliary lymph nodes, kidneys, pancreas and lung were dissected and removed. 

4.2.4.2.	Processing of tumour tissue derived from mice 
Tumour tissues dissected from mice were fixed in 10% formalin overnight.  The following day, fixed tissue samples were trimmed and placed within embedded cassettes and processed on a Shandon processor. The tissues were washed in following stages:
	70% ethanol for 1 hour.
	90% ethanol for 1 hour.
	Absolute ethanol for 4 X 1 hours.
	Xylene for 3 X 1 hours.
	Warm paraffin wax (60%) for 2 X 1.5 hours.
Then the processed tissues were embedded in paraffin wax at 60oC and cooled on ice.  Paraffin embedded tissues were cut into 4µm sections in microtome. Sections were stained with Gill’s haematoxylin and eosin (H and E) for microscopic examination.

4.2.5.	Apoptosis study
In this study Annexin V-FITC apoptosis detection kit (BioVision) was used for labelling apoptotic cells according to the suggested protocol and using the reagents from the kit.  This system utilized the observation that upon initiating apoptosis, membrane phosphatidylserine (PS) was translocated from the inner surface of plasma membrane to the cell surface, where it could bind to a fluorescent conjugate of Annexin V and be detected using either flow cytometry or fluorescent microscopy.  

4.2.5.1.	Measurement of degree of apoptosis without induction
From each transfected cell line and empty vector cell line, cells were counted and volumes containing 4 X 106 cells were centrifuged into pellets and the media was removed.  Pellets were resuspended in 5 ml of PBS in order to wash the cells from traces of growth media containing foetal calf serum.  The tubes were centrifuged again and the supernatant was removed. Cells were resuspended in 500 µl of binding buffer provided in the kit.  From Annexin V-FITC and propidium iodide (PI) solutions 5 µl were added to the cell/buffer mixture and incubated at room temperature for 10 minutes in the dark.  Using control cell line sample, and performing one round of fluorescent detection in flow cytometer, following adjustmens were made in Scatter gram, FL1 and FL3 histograms:  
	Graph of Forward Scatter versus Side Scatter was gated to exclude cell debris or very large particles with could be cell clumps from the graph.  These unwanted cells would be detected in the lower left hand corner and upper right hand corner of the gate respectively.
	On FL1 and FL3 log histograms, the voltage was adjusted to put the graphs in the right position.  Usually when the right hand edge of the histogram falls on 101 the histogram is considered in optimal position.  
	On FL1 log histogram the horizontal lines B and C indicating the boundary of normal cells and apoptotic cells were adjusted, so that the right edge of line B and left edge of line C fall at correct position between two histograms. 
These setting were saved and used as constant setting throughout the experiment in order to make the measurements comparable.  Flow cytometry was repeated for transfected cell line samples and control cell line.  Annexin V-FITC binding was analyzed by FITC detector (FL1) and PI staining by the phycoerythrin emission signal detector (FL2).

4.2.5.2.	Measurement of apoptosis rate with induction

The cytotoxin champtothecin was used to induce apoptosis.  First the amount of champtothecin that was necessary to induce apoptosis in the control cell line was titrated. 
From the control Empty Vector cell line, 6 X 10ml dishes were cultured with 4 X 106 cells in 10 ml growth media.   Different volumes 2mM champtothecin was added to the labelled dishes to make serial concentrations of 4, 10, 20, 30, 40 and 60 µM and mixed by gently swirling. The dishes were incubated in 37oC incubator for approximately 16 hours.  Then the degree of apoptosis was measured by analysing Annexin V-FITC binding using flow cytometry as described above.







The relative expression of Id3 mRNA in different transient transcription samples and GLC-19 parental cell line is demonstrated in Figure 4.9. 
According to this result, plasmid containing target 18 siRNA oligonucleotide was chosen to be used in stable transfection experiment.  Since the transfection efficiency was sufficient (80%) after 24 hours it was determined as the optimal length of transfection.  

Figure 4.9: Relative expression of Id3 mRNA in transiently transfected cells using different siRNA targets and different experimental length.  According to the graph the target 18 and 20 gave the best knock down.  





Eight transfected cell lines showed more than 60% decrease in relative mRNA Id3 levels comparing to the empty vector (EV) cell line.  from these, seven cell lines showed closely similar levels of Id3 as normal epithelial cell line, Beas-2b.
Two cell lines, G-Id3-1 and -7 were selected for protein measurement.  G-Id3-1 was selected as an intermediate knock down and G-Id3-7 cell line was picked randomly among cell lines with similar levels of Id3. 
Figure 4.10 shows the graphic results of relative expression of Id3.

Figure 4.10 : Relative mRNA expression of Id3 in GLC19 si-Id3 colonies compared to GLC19 parental cells, empty vector (EV), and normal epithelial Beas-2b cell lines.

4.3.2.2.	Id3 protein expression in GLC-19 si-Id3 cell lines


Western blot showed more than 65% reduction of relative Id3 protein expression in si-Id3 transfected cell lines compared to empty vector cell line in which Id3 protein expression was measured as similar level as parental cell line GLC-19. 
















Figure 4.11:  A) Relative protein expression of Id3 in si-Id3, parental and Empty Vector cell lines.  B) Representative Western blot picture of Id3 protein expression in si-Id3, GLC-19 and empty vector (EV) cell lines.  

4.3.2.3.	Id1 and Id2 protein expression in si-Id3 cell lines
Using anti Id1 and Id2 antibodies in two sets of Western blot experiments showed that the relative levels of these proteins were not significantly changed in cell lines with knockdown levels of Id3 protein. This result indicates that the changes in malignant behaviour of si-Id3 cell lines are independent to the other Id proteins and are the direct result from reduction of Id3 protein levels in these cell lines (Figure 4.12).








To assess the effect of reducing Id3 expression in proliferation ability of GLC-19 cells proliferation assay was performed.  Starting with 5000 cells for each cell line, the number of cells on day 8 of the experiment was more than 45000 cells in parental cell line and empty vector cell line, while in both transfected cell line, cell numbers didn’t reach 20000.  This indicated more than two fold fall in growth rate in si-Id3 cell lines compared to control cell line.  When tested in student t-test, these reductions were statistically significant (ρ < 0.001) for the difference between both G-Id3-1 and G-Id3-7 cell lines and control cell line.
The difference between GLC-19 parental cell line and the empty vector control cell line wasn’t significant.  The final cell counts and statistical comparison are summarised in 4.3.  The growth graphs for transfected cells and control cells and the final numbers of cells in each cell line are shown in Figure 4.13. 

Table 4.3:  Summary of final cell count and statistical analysis of MTS proliferation assay using GLC-19 si-Id3 colonies. ρ values are the results of unpaired Student t-test.  (**  Statistically not significant).








Figure 4.13: MTS Proliferation Assay.  Graphs show the difference between growth rate of si-Id3 transfected cell lines, GLC-19 parental cell lines and EV control cell line.  Error bars indicate the standard deviation between triplet samples in each cell line.  The experiment was started with 5000 cells for each cell line.  Final numbers of cells at day 8 are demonstrated.

4.3.3.2.	Soft Agar assay
To evaluate the ability of si-Id3 transfected cell lines to produce colonies in soft agar as an indication for tumourigenisity, low melting temperature soft agar assay was performed.  Empty vector cell line produced 94 colonies in average which was significantly higher than G-Id3-1 with 14 colonies and G-Id3-7 with 55 colonies with ρ values less than 0.001 and 0.01 respectively, both statistically significant.  These results are summarised in Table 4.4 and demonstrated graphically in Figure 4.14.  
Figure 4.15 demonstrates the pictures from soft agar dishes.

Table 4.4: Number of colonies formed in soft agar counted for si-Id3 transfected cells, GLC-19 parental cells and EV cell line and the ρ value of their difference to EV cell line.  




Empty Vector	94 ± 12.9	Not applicable
















To investigate the consequences of Id3 reduction in tumourigenisity of GLC-19 cells within a live animal,  si-Id3 transfected cell lines and empty vector control cell line were inoculated into three groups of male immune-compromised nude mice and the growth of tumours were observed and measured. 
The size of tumours were calculated twice a week, using formula: Volume = π/6 (H x W)3/2 0.67 where H x W stands for height x width in milimeters.
After the first week of inoculation the control cell line started to grow much faster than the transfected cell lines.  On day 18 the size of the tumours in cell lines with reduced Id3 level was significantly smaller than the empty vector control cell line with two-tailed ρ values of 0.0033 and 0.001 for the differences between G-Id3-1 and G-Id3-7, and empty vector cell line respectively when tested in unpaired student t-test. 










To investigate whether an increase in the degree of apoptosis plays any role in reducing growth rate and proliferation of si-Id3 transfected cell line two sets of experiments were performed. First the degree of apoptosis in transfected cell lines was compared to empty vector control cell line without induction of apoptosis.  In this experiment the results didn’t show any significant difference between transfected cells and control cells (Figure 4.18). 
Second the degree of apoptosis after treatment with camtothecin, an apoptosis inducing reagent, was examined.  First the optimal concentration of chamthoticine was obtained by incubating the control cell line overnight with different volumes of 2mM camtothecin.  The first four concentrations, 4,10,20 and 30 µM didn’t induce any apoptotic peaks in flow cytometry.  The next two concentrations of 40 and 60 µM appeared to have induced some apoptosis .....in the cell population (Figure 4.19).  Therefore the lower concentration, 40 µM was chosen as the optimal concentration for camptothecin.




















































This study was undertaken to examine the role of Id family proteins in pathogenesis of SCLC.  The first part of the study showed that Id1, Id2 and Id3 were overexpressed in malignant SCLC cell lines when compared to normal bronchial epithelial cell line.  Tissue expression of all 4 proteins were assessed as up-regulated in malignant SCLC tissue sections in comparison to normal bronchial epithelial sections from the same patients in 26 pairs of tissue sections. Immunohistochemical staining of large number of SCLC biopsy samples showed the same pattern of expression for each Id protein as in the tissue sections.  Kaplan Meyer survival analysis of these biopsy samples showed a positive correlation between moderate/strong cytoplasmic expression of Id2 and patients’ survival period.  According to these findings it was concluded that Id family proteins’ expression was related to malignant phenotype of SCLC and therefore might have a role in pathogenesis of this cancer.  
The second part of the study focused on Id3 protein to test the hypothesis that reducing expression of this protein in SCLC would reduce the tumourigenisity of this cancer in vitro and in vivo. Using si-RNA technique, two cell lines were established with significant lower expressions of Id3 compared to their parental cell line GLC-19, a malignant SCLC cell line.  These cell lines were used alongside an empty vector cell line in a series of in vitro and in vivo studies.  Proliferation assay and soft agar assay both showed significantly lower growth rate and colony counts respectively in knock down cell lines compared to the empty vector cell line.  The reduced Id3 expression cell lines also produced significantly smaller tumours when inoculated to nude mice.  These results collectively confirmed the hypothesis and showed that Id3 expression is correlated with malignant behaviour in SCLC.  Apoptosis study on the same si-Id3 cell lines showed that these cell lines were more sensitive to apoptosis induction by cytotoxic reagent champtothecin.  This indicated that levels of Id3 might be important in drug sensitivity in SCLC treatment. 
Small cell lung cancer has been described  as a “forgotten disease” (Rosti et al. 2006) since for the last ten years, the basic knowledge and treatment tactics for this cancer have faced a plateau. Many attempts to understand its molecular biology has been made, but little is found in terms of mechanisms involved in rapid disseminative nature of this devastating disease.  Moreover, despite of some early good results regarding some new treatment strategies, no breakthrough has followed later on and new reagents have not been able to increased general survival time of treated patients comparing to old drugs.  Therefore the only way to go forward is to find new therapeutic approaches or diagnostic tools based on novel molecular mechanisms involved in initiation and progression of SCLC.  
There have been some discrepancies about the origins of small cell lung cancer.  Some have  categorised this disease alongside other neuroendocrine tumours of the lung, coming from widely-dispersed population of neuroendocrine cells integrated in the respiratory epithelium  called Kulchitzky cells (Paladugu et al. 1985) or amine precursor uptake and decarboxylase ( APUD) cells (Bombardieri et al. 1995).  However, opinion is now swinging in favor of an endodermal origin (Brambilla et al. 2000). Gene expression profile of SCLC has been found to be much more closely related to epithelial cells in contrast to benign neuroendocrine pulmonary tumours, carcinoids, which appear to be more associated with neural-crest derived brain tumours. According to this observation, it has been proposed that SCLC is an epithelial carcinoma rather than descended from neural crest (Anbazhagan et al. 1999).  Therefore the normal bronchial epithelial tissue and cell line are reasonable candidates to be compared with malignant SCLC tissue sections and cell lines when genes related to malignant transformation of this cancer are being studied.
SCLCs are not accompanied by specific pre-neoplastic changes  ADDIN EN.CITE (Wistuba et al. 2001; Koutsami et al. 2002). When normal epithelium accompanying malignant tumour was assessed for genetic damages including allelic loss and microsatellite alterations, it was found that the most extensive damage presented in normal epithelium of SCLC patients comparing to the other major lung cancers.  Due to this extensive, accumulative DNA damage SCLCs may originate from either normal or hyperplastic epithelia, without passing through characteristic pre-neoplastic changes  ADDIN EN.CITE (Wistuba et al. 2000).  This was called the parallel theory of lung cancer development in contrast to sequential theory that is proposed for NSCLC.  The latter involves a sequence of morphological intermediate steps before malignant transformation, which is referred to as preneoplastic lesion.  
On the other hand there seem to be a chronological sequence of genetic changes related to SCLC.  The earliest genetic alterations reported during carcinogenesis of SCLC are allele losses and microsatellite alterations.  These usually happen at important chromosomal sites which belong to genes involved in growth-inhibitory pathways resulting in their inactivation and abnormal cell proliferation.  3p deletion is one of the earliest events related to this malignancy (Hurr et al. 1996).  Aberration of pRB pathway due to events such as inactivation of p16 proceeds p53 mutation at very early stages of SCLC.  These events lead to disruption of the control between G1 to S phase  ADDIN EN.CITE (Barbareschi et al. 1992).  Inversely MYC amplification (Testa et al. 1997) and impairment of E-cadherin-catenin complex (Koutsami et al. 2002) are late events associated with tumour invasion and metastasis, so are downregulation of BCL-2 and BAX leading to attenuation of apoptosis (Pal'tsev et al. 2000).  High telomerase activity (Hirashima et al. 2001), and expression of MMPs, ETS and c-erbB-2  ADDIN EN.CITE (Bolon et al. 1995; Micke et al. 2001) are other late events detected more often in extensive disease and related to tumour invasion (Figure 5.1).

Figure 5.1: Genetic events leading to small cell lung cancer, copied from (Koutsami et al. 2002)

Despite of all the efforts that have been made to discover the key genetic factors that are responsible for highly malignant and disseminative nature of SCLC they are not known so far.  The first part of this study used a preliminary result of a differential display experiment that was performed in search for new genes/genetic pathways involved in pathogenesis of SCLC. The differential display result indicated that mRNA of Id1, a dominant negative regulatory transcription factor from Id family proteins, was expressed higher in SCLC malignant cell line Lu-165 comparing to Beas-2b cells, a normal bronchial epithelial cell line.  In order to validate and extend this result western blot technique was exploited to investigate expression of the gene at the protein level in a wide range of malignant cell lines (n=10) comparing to Beas-2b cells.  The result was consistent with that of the differential display, showing overexpression of Id1 protein in 8 out of 10 malignant cell lines.  Immunohistochemistry indicated higher degrees of Id1 expression in cytoplasm of malignant cells but higher levels of the protein in nuclei of the normal epithelial cells of the same patients.  Considering the western blot outcome, which measures the whole protein content of the cell, the general trend in Id1 expression was evaluated as over-expressed in malignant SCLC.  
This result was repeated for other members of Id family proteins, Id2, Id3 and Id4.  Id2 and Id3 showed overexpression in both malignant SCLC cell lines and tissue sections in comparison to normal epithelial counterparts.  Western blot couldn’t clearly show expression status of Id4, since the corresponding bands detected in malignant cell lines were too faint to be measurable. The low levels of this protein was also observed in immunohistochemistry where staining of Id4 was generally weak to moderate. However, low levels of this protein couldn’t rule out its possible significant role in malignant transformation.  Other studies have also put Id4 in a distinctive league as other Id proteins despite their similar molecular structure and mechanism of function.  During embryogenesis, while the other Id proteins are expressed in peripheral tissues and their distributions are overlapping, Id4 shows a unique pattern being selectively expressed in the nervous system  ADDIN EN.CITE (Jen et al. 1996).  Similarly in adult organs Id4 is expressed mostly in testis, brain and kidney, a pattern different from restricted expression of Id2 as well as from the widespread expression of Id1 and Id3  ADDIN EN.CITE (Riechmann et al. 1994).  Regarding its function, in contrast to other Id proteins a correlation between Id4 expression and cell growth has not been identified so far  ADDIN EN.CITE (Zebedee et al. 2001).  Therefore Id4 might be important in other aspects of tumourigenesis such as invasion and metastasis, as it is suggested in prostate cancer (Yuen et al. 2006).  
The other finding in the first part of this study was the survival significance of Id2 overexpression which was directly correlated to longer survival for SCLC patients.  Expression of other three Id proteins wasn’t associated with better or worse patients’ outcome.  The results of first part of this study have been discussed in details in chapter 2.
Id3 was the focus of second part of this study, in which the aim was to determine the consequences of decreased levels of Id3 protein in SCLC cell lines.   Using siRNA technique, a vector containing an oligonucleotide sequence targeting Id3 was transfected into a malignant SCLC cell line, GLC-19, which had shown the highest levels of Id3 amongst 10 malignant cell lines.  Two cell lines with decreased levels of Id3 to 30% of the control cell line were established and used in a series of in vitro and in vivo experiments.  Soft agar tumourigenesis assay showed significant decrement in number of colonies grown from transfected cell lines comparing to control cells.  Proliferation assay also demonstrated 2.5 to 3 fold fall in the number of si-1d3 cells counted on day 8 of experiment in contrast to the control cell line.  Both these results indicated that Id3 clearly affected growth rate of malignant cell lines.  Moreover, as a tumourigenesis indicator, soft agar assay results suggested that levels of Id3 protein changed the ability of malignant cells to grow in an anchorage independent environment.  
When inoculated into mice, si-Id3 transfected cell lines produced tumours which were significantly smaller than the control cell line.  This finding was in the same trend with in vitro results and confirmed that Id3 levels related to proliferation ability of tumour cells. All these changes were independent of the level of other Id proteins, since Id1 and Id2 expression didn’t significantly change in si-Id3 transfected cell lines.      
When a change of growth rate is observed in a group of cells, two logical possibilities are feasible.  One is alteration in cell division rate through cell cycle regulation, and second is a shift in rate of apoptosis.  Apoptosis study using Anexin-V apotosis labeling method ruled out the second hypothesis, since flow cytometry didn’t detect any differences in the percentage of apoptotic cells between si-Id3 cell lines and the control cell line.   Therefore reduced proliferation rate remains the only logical explanation for in vitro and in vivo experiment results, which point toward reduced growth rate in Id3 depleted cells unanimously.   
Id3 previously has been related to cell cycle regulation.  This regulation mostly has been explained by pathways involving Id3 in relation to one of CDK inhibitors such as p16 or p27.  For example disruption of Id1 and Id3 upregulates p16 in mouse embryonic brain which results in impairment of neurogenesis  ADDIN EN.CITE (Lyden et al. 1999).  In most studies Id3 has been examined alongside Id1 and their proliferative effects have been linked together, except for a study using Xenopus model in which Id3 is the only Id protein expressed during neural crest development.  In this model Id3 depletion caused absence of neural crest precursors and loss of neural crest derivatives due to cell cycle inhibition and cell death.   Id3 depletion was accompanied by ectopic expression of cell cycle inhibitor p27 suggesting a negative regulatory role for Id3 on p27 transcription. Conversely overexpression of Id3 increased cell proliferation and resulted in expansion of the neural crest domain  ADDIN EN.CITE (Kee et al. 2005).    
Using a wounding model as an inducer of cell-cycle entry for human dermal fibroblasts, when Id3 was silenced, the expected downregulation of p27didn’t happen, suggesting the transcription repression of p27 was regulated by Id3. It was also found that both G1 phase progression and G1/S transition was blocked by Id3 depletion (Chassot et al. 2007).  
In contrast to Id2 that directly interacts with anti-proliferative RB protein, Id1 and Id3 apply their positive cell cycle regulatory effect indirectly, by binding to and inhibiting ETS transcription factors or activating EGR-1 promoter.  In this way they inactivate CDK inhibitors such as p16, p21 or p27 which in turn, result in phosphorylation of RB, liberation of Id2 and cell proliferation.  MYC ancogene has been shown to utilize this effect in carcinogenesis by upregulating Id3 protein.  In this manner hypothetically Id3 can suppress E2A factors involved in differentiation, growth suppression and apoptosis (Ruzinova et al. 2003).  Further proof to this notion was provided by an experiment on LNCaP, a benign prostate cancer cell line, where silencing Id3 resulted in increment of p16 and p21 levels, suggesting this might be the mechanism of proliferation reduction upon Id3 knockdown.  Similar to the present study, this result was also independent of level of other Id proteins  ADDIN EN.CITE (Asirvatham et al. 2007). 
In the current study one can speculate that the significant growth reduction in si-Id3 transfected cell lines has been a result of elevation of inhibitory effect of this protein on transcription factors regulating CDK inhibitors resulting in cell cycle inhibition.  However, since RB gene is already mutated and inactivated in 98% of SCLC cases, it is very unlikely that proliferation reduction in Id3 knock down cells is a result of RB activation.  
Id1 and Id3 have partial overlapping functions in terms of regulation of proliferation in human prostate cancer  ADDIN EN.CITE (Asirvatham et al. 2006) and also during normal development.  Since levels of Id1 and Id2 didn’t change by silencing Id3, there is a possibility that ld1 compensated to some extent for growth reduction in Id3 depleted cells, resulting in some, although much slower, growth in those cells.  




In contrast to the extensive study of Id proteins in other cancers, their possible involvement in the development and metastasis of SCLC has not been previously investigated. In this study first the general expression status of Id family proteins was investigated.  Western blot and immunohistochemistry results showed overexpression of Id1, Id2 and Id3 proteins in malignant SCLC cell lines and tissue sections comparing to normal bronchial epithelial cell line or normal bronchial margin from the same patient respectively.  Id4 was overexpressed in malignant tissue sections but its expression level couldn’t be measured in malignant cell lines.  Thus the increased expression of these four Id proteins was associated with the malignant characteristics of the cells, indicating they may play some roles the cancer’s malignant transformation.  Considering different intra cellular localization of each protein, the author of this thesis concluded that not only higher levels Ids, but also the subcellular localization of these proteins might be important in tumourigenisity of SCLC.  This notion was particularly supported by survival analysis that indicated longer survival associated with high levels of Id2 expression, which located almost exclusively in the cytoplasm in contrast to Id1, Id3 and Id4 which showed nuclear expressions as well. 
Second part of the study focused on Id3, since it presented the strongest case in terms of overexpression in both cell lines and tissue sections, and its expression was mostly in the nuclei, where Id proteins are functional.  Second reason behind this choice was the lack of previous investigations focusing on this protein in cancer comparing to the other members of Id protein family.  
By knocking down Id3 protein expression using si-RNA technique, two cell lines were established that expressed 70% less Id3 protein than the control cell line.   Using these cell lines in soft agar assay and proliferation assay, both cell lines showed considerable lower rates of proliferation and anchorage independent growth in contrast to the control cell line.  They also created significantly smaller tumours than the control cells when injected into nude mice.  The highlight of these results was that Id3 depletion caused slower growth rate of tumour cells both in a culture dish and within a live animal.  These effects where independent of levels of other Id proteins.  
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APPENDIX I: Chemical Used in Methods Section
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MTS proliferation assay on si-Id3 cell lines

In vivo assay: Tumour growth of si-Id3 cell  lines 

Figure 4:17: In vivo assay; tumours produced in nude mice after inoculation of si-Id3 cell lines into the animal’s shoulder area.  Each picture is a representative from one group.  Tumour sizes are noticeably smaller in si-Id3 groups compared to the empty vector group.

Figure 4.18:  Degree of apoptosis in empty vector (I), G-Id3-1 (II) and G-Id3-7 (III) cell lines without apoptosis induction.  No apoptosis peaks are detectable in any of the cell lines.

Figure 4.20:  Apoptosis study using 40 µM champtothecin to induce apoptosis in si-Id3 cell lines (II and III) and empty vector cell line (I).  The percentage of apoptotic cells indicated by percentage of gated cells in region C of FL1 log have increased more than 2 fold in si-Id3 cell lines when compared to empty vector cell line.
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